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 INTRODUCTION 
 Strokes are the most important cause of prolonged disability. About 
15% to 25% of stroke survivors become disabled permanently, while 
20%remain in institutional care for three months after their stroke. The 
psychological and economical burdens of stroke are enormous. Stroke is one 
of the major illnesses in all over the world. Stroke is the most common cause 
of death after cardiac disease and cancer. It plays an important role in the 
morbidity and mortality in the elderly and late middle age persons. 
Cerebrovascular disease stands first in frequency among the neurologic 
diseases.  
 Because of the raising in the number of aging population, the burden of 
stroke is likely to increase automatically in the near future. Early 
identification of risk factors associated with stroke and implementing 
prevention programs will definitely help to control the burden of this major 
epidemic. Stroke is a heterogeneous disease. Ischemic and hemorrhagic 
strokes are the two major types of stroke with different pathogenesis and 
outcome. 
 Various studies demonstrate an association between fibrinogen levels 
and ischemic stroke prognosis. Every study shows a worse in prognosis in 
ischemic stroke patients with high fibrinogen level at the time of stroke. 
 This study attempts to identify the significance of plasma fibrinogen as 
a risk factor as well as prognostic factor for ischemic stroke patients and also 
to study the correlation between the plasma fibrinogen levels and other major 
risk factors for ischemic stroke. 
 The primary goal of biomarker plasma fibrinogen in ischemic stroke 
patients is early identification of high risk individuals who can be targeted for 
aggressive acute management and improved secondary prevention measures. 
Many secondary prevention interventions
62
  in particular diet, exercise, 
smoking cessation and drugs [fibrates, omega 3 fatty acids, ticlopidine and 
pentoxifylline]
61
 all reduce fibrinogen levels and minimize vascular risk. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
AIM OF THE STUDY 
 
 To study the significance of plasma fibrinogen in ischemic stroke 
patients as a risk factor. 
          To study the correlation of plasma fibrinogen in ischemic stroke with 
special reference to risk factors such as age, sex, smoking, alcoholism, 
hypertension, diabetes mellitus and obesity. 
 To study the correlation between initial fibrinogen levels and 
functional outcome and severity of ischemic stroke. 
REVIEW OF LITERATURE 
 Cerebrovascular disease most commonly presents as an acute focal 
stroke. Stroke is a clinical syndrome characterized by acute loss of focal brain 
function or monocular function with symptoms lasting more than 24 hours. It 
is due to inadequate cerebral or ocular blood supply. The clinical symptoms 
of stroke are highly variable because of the complex anatomy of the brain and 
its vasculature. About 85% of all stroke are ischemic 10% are due to intra 
cerebral hemorrhage and 5% are due to subarachnoid hemorrhage in the 
community. Ischemic arterial disease may present, particularly in elderly with 
a gradual decline in intellectual function with motor weakness or with or 
without sensory weakness or gait disorder. Hemorrhagic stroke occurs mostly 
due to rupture of the major cerebral arteries of the circle of Willis in to the 
subarachnoid space. 
 Cerebral ischemia is caused by a prolonged reduction in blood supply 
that lasts longer than several seconds. Neurological symptoms manifest 
within seconds when the neurons are devoid of glycogen and ATP. 
 The normal cerebral blood flow (CBF) in man is 50ml/100gms of 
brain/min. Using Positron Emission Tomography, the cerebral energy 
metabolism is evaluated by cerebral metabolic rate of oxygen (CMRO2) and 
of glucose (CMR glu). It has also been found that the oxygen extraction 
fraction (OEF) remains constant throughout the brain. So in resting normal 
brain, the CBF is a reliable reflection of CMRO2. 
 In ischemia when CBF reduces below about 20ml/100g/min, the 
oxygen extraction fraction becomes higher and the CMRO2 begins to reduce. 
Infact a high OEF is only seen nearly after acute ischemic stroke, in the first 
day or so. If the blood supply is restored, functional recovery is still possible. 
If blood flow is quickly restored brain tissue can recover fully and patient’s 
symptoms are only transient; it is defined as transient ischemic attack [TIA].  
 Typically the neurologic signs and symptoms of a TIA last for 5 to 15 
minutes. But by definition symptoms should recover within less than 24 
hours. Stroke will occur when the signs and symptoms last for more than 
24hours. Focal ischemia or infarction is usually caused by thrombosis of the 
cerebral vessels or by emboli from proximal arteries or heart. 
 In ischemia, due to ineffective anaerobic metabolism of glucose, 
lactate synthesis increases and the pH falls. ATP synthesis is impaired. As the 
cerebral blood flow reduces further, energy-dependent functions of the cell 
membranes become increasingly damaged. Water, Sodium, calcium and 
Chloride enter the cells and Potassium (K+) leaks out. Potentially neurotoxic 
transmitters such as L-glutamate, oxygen radicals and lipid peroxides are 
formed and will damage the cells further. 
  Fall in cerebral blood flow to zero cause infarction within 4 to 10min. 
When cerebral blood flow less than 16 to 18ml/100g tissue per min cause 
infarction within 60 minutes. When the blood supply becomes further less 
than 10ml/100gm/min, infarction occurs and if blood flow is restored, 
neurological function does not come back. At this point, the CMRO2 and 
CMF will be low and OEF will be normal indicating metabolic depression. 
 Sometimes oxygen extraction fraction is low and the cerebral blood 
flow is in excess of requirements for the low metabolic demands of the 
infarcted tissue. It is known as luxury perfusion. In absolute luxury perfusion, 
CBF is increased which is termed as hyper perfusion. 
Factors determining the metabolic consequences. 
1. Duration of ischemia 
2. Collateral blood supply  
3. Development of cerebral edema  
4. Raised intracranial pressure 
5. Vasoconstrictor prostaglandins released from aggregating platelets and  
6. Blood viscosity and aggregation of formed elements slow the 
microcirculation and promote thrombosis 
7. Hyperglycemia of stress response reflect the severity of initial stroke 
8. Systemic hypoxia (as a consequence of pneumonia etc.) and  
9. Dehydration by, increasing the hematocrit and blood viscosity. 
10. Free radical damage. 
Free Radical Damage 
Three major molecular events in brain damage from cerebrovascular 
occlusion are  
1. Calcium overload, 
2. Excessive acidosis, and  
3. Enhanced production of free radicals. 
 Free radicals are produced in increased amounts under ischemic 
conditions and damage proteins, nucleic acids, and membrane lipids, 
disrupting cellular integrity. This oxygen radical activity is especially very 
intense during reperfusion after sustained ischemia. The generation of 
hydroxyl radical, the most toxic and reactive of free radicals, is catalyzed by 
ferrous iron released from intra cellular stores during ischemia. Brain cells 
release glutamate as a result of stroke and glutamate initiates biochemical 
reactions that lead to brain cell death, including the production of free 
radicals.  
          Typically the neurological signs and symptoms of a TIA last for 5 to 15 
minutes. But by definition symptoms should recover within less than 24 
hours. Stroke has occurred when the signs and symptoms last for more than 
24 hours. Focal ischemia or infarction is usually caused by thrombosis of the 
cerebral vessels or by emboli from proximal arteries or heart. 
  Cerebral hemorrhage produces neurologic symptoms by producing a 
mass effect on neural structures or from the toxic effects of blood itself. 
BLOOD SUPPLY TO BRAIN 
Anterior circulation - by means of one internal carotid artery each 
side. Each one supplies two fifths of total circulation of brain. 
Posterior circulation - by means of two vertebral arteries which join 
to form basilar artery. It accounts for one fifth of total brain circulation. 
It is important to note that the posterior circulation contains the brain 
stem, a midline important crucial structure. 
CIRCLE OF WILLIS: 
 Most important circle of Willis
1 
lies in the inter peduncular fossa at the 
base of the brain. This circle is formed by anastomosis between the two 
internal carotid arteries and the two vertebral arteries. The anterior 
communicating artery, the anterior cerebral, internal carotid, posterior 
communicating, posterior cerebral and the basilar arteries all contribute to the 
circle. The circle of Willis allows blood that enters either by the internal 
carotid or by the vertebral arteries to be distributed to any part of either 
cerebral hemisphere. Circle of Willis also gives cortical and central branches 
that supply the brain. 
CAROTID ARTERIAL SYSTEM: 
 The left common carotid artery originates directly from the aorta and 
right common carotid artery from the innominate artery. At the bifurcation of 
the common carotid artery, the internal carotid artery starts at the carotid 
sinus then it runs up the neck and reaches the base of the skull and reaches 
the carotid canal of the petrous bone. It then runs through the cavernous 
sinus, pierces the meninges and divides into anterior and middle cerebral 
arteries. 

BRANCHES OF INTERNAL CAROTID ARTERY 
OPHTHALMIC ARTERY: 
         The ophthalmic artery is the first main branch of the ICA. It arises in 
the cavernous sinus. It goes through the optic foramen to supply the eye and 
other structures in the orbit. 
POSTERIOR COMMUNICATING ARTERY: 
 It is the next artery to branch from the internal carotid artery. It runs 
back to communicate the first part of the posterior cerebral artery, so 
contributing to the circle of Willis. 
ANTERIOR CHOROIDAL ARTERY: 
 This develops from the last portion of the internal carotid artery and 
supplies optic tract, internal capsule, parts of basal ganglia, thalamus and 
optic radiation. 
ANTERIOR CEREBRAL ARTERY: 
 The anterior cerebral artery goes to the inter-hemispheric fissure, joins 
with its counterpart of opposite anterior cerebral artery via anterior 
communicating  artery, curves around the genu of corpus callosum  and 
supplies the anterior and medial parts of the cerebral hemisphere. 
MIDDLE CEREBRAL ARTERY 
 The middle cerebral artery goes to the sylvan fissure and gives 
branches which supply the lateral parts of the cerebral hemisphere. From its 
main trunk a medial and lateral group of tiny lenticulostriate arteries arise and 
pass upwards to penetrate the base of the brain and the supply the basal 
ganglia and internal capsule. The artery gives blood supply to the whole of 
the motor cortex except the leg area. 
VERTEBRO BASILAR SYSTEM: 
VERTEBRAL ARTERY: 
            The vertebral artery, a branch of the proximal subclavian artery 
ascends to pass through the transverse foramina of the sixth to the second 
cervical vertebrae, giving off small muscular branches on its ascend up. It 
runs posteriorly around the atlas and enters the skull through the foramen 
magnum. It joins with the opposite vertebral artery on the vertebral surface of 
the brainstem to form the basilar artery. The vertebral artery gives branches 
to anterior and posterior spinal arteries, the posterior inferior cerebellar 
arteries and small penetrating branches to the medulla
2
. 
BASILAR ARTERY 
 The basilar artery runs ventral to the pons to the pontomidbrain 
junction in the inter peduncular cistern. It bifurcates there and gives two 
posterior cerebral arteries. Numerous small branches are given to the brain 
stem and cerebellum. It gives rise to the anterior inferior cerebellar artery and 
superior cerebellar artery. 
POSTERIOR CEREBRAL ARTERY: 
 The posterior cerebral artery surrounds the midbrain close to the 
oculomotor nerve at the level of tentorium and gives blood supply to the 
inferior part of the temporal lobe and the occipital lobe
3
. Many small 
branches supply the mid brain, thalamus, hypothalamus and geniculate 
bodies. 
ARTERIES TO SPECIFIC BRAIN AREAS 
Corpus striatum and internal capsule- medial and lateral striate central 
branch of the middle cerebral artery supply
4
; the central branches of the 
anterior cerebral artery supply the remainder of the structures. 
Thalamus -The posterior cerebral, posterior communication and basilar 
arteries supply the thalamus. 
Mid brain - The posterior cerebral, superior cerebellar and basilar arteries 
supply. 
Pons - The basilar and anterior, inferior and superior cerebellar arteries 
supply the pons. 
Medulla oblongata- The vertebral, anterior and posterior spinal, posterior 
inferior cerebellar and basilar arteries supply. 
VEINS OF THE BRAIN 
EXTERNAL CEREBRAL VEINS 
 Superior cerebral veins run upward over the lateral surface of the 
cerebral hemisphere and empty into the superior sagittal sinus. The 
Superficial middle cerebral veins empty the lateral surface of the cerebral 
hemisphere; it run inferiorly in the lateral sulcus and empty into the 
cavernous sinus. Deep middle cerebral veins the insula and is joined by the 
anterior cerebral vein and striate veins to form the basilar vein. Basilar vein 
ultimately joins the great cerebral vein, which in turn drains into the straight 
sinus. 
INTERNAL CEREBRAL VEINS: 
 There are two internal cerebral veins. Union of the thalamo striate vein 
and the choroidal vein at the interventricular foramen forms internal cerebral 
veins. These veins form the great cerebral vein that drains into the straight 
sinus. 
EPIDEMIOLOGY 
INCIDENCE OF STROKE: 
 Worldwide, stroke is the major disease. Ischemic stroke is the major 
determinant to disability, morbidity and mortality in the world
5
. The 
incidence of stroke rapidly rises with the age. About 25% incidence occurs 
below the age of 65 and 75% above the age of 65years. 
   In 1990 CVD cause 28% of the world's 50.4 million deaths and 9.7% 
of the 1.4 billion lost DALYs. In the year 2001, CVD was the cause for 29% 
of all deaths and 14 % of the 1.5 billion lost DALYs. By the year 2020, 32 % 
of all deaths will be due to CVD. 
 WHO estimates that CVD will cause totally 24.2million deaths by the 
year 2030 in the world. Of these,14.9 % of deaths in men and 13.1 % of 
deaths in women will be due to CHD. Stroke will be responsible for 10.4 % 
of all male deaths and 11.8 % of all female deaths. 
 The population based study was done by WHO collaborative study in 
Rohtak; in Haryana state [1971-74] showed an annual incidence of 33 per one 
lakh population per year. 
 Leeder compared the role of CVD in the death patterns of one low-
income country(India) and four middle-income countries (Russia, Brazil, 
China, and South Africa) in 2000 and predicted that increase in the number of 
productive years lost due to CVD between 2000 and 2030 in India compared 
to other countries. South Africa, 28 %; China, 57 %; Brazil, 64 %; and India, 
95%. 
STROKE PREVALENCE: 
 Vellore study demonstrated that stroke prevalence rate per 1lakh 
population was 56.9 per 1,00,000 population. The prevalence in Indian 
Eastern part was 160-270 per 1, 00,000 population. 
 South Asians have a high prevalence of ischemic stroke, coronary heart 
disease, non-insulin-dependent diabetes, central obesity, insulin resistance, 
hypertension
6
 and high stroke mortality. It seems to be due partly to genetic 
susceptibility of high lipoprotein(a) levels in south asians and also influenced 
by dietary and life style induced changes in lipid levels. 
MORTALITY 
 WHO collaborative study described that both in developed and 
developing nations, nearly 33% of the stroke patients died within 3 weeks 
and 48 percent expired within one year. Stroke is one of the topmost causes 
of death throughout the world.  
RISK FACTORS FOR STROKE 
AGE: 
          Age is one of the strongest risk factor for ischemic stroke, primary intra 
cerebral hemorrhage and subarachnoid hemorrhage
7
. It is one of the major 
factors which negatively influence the outcome of the stroke patients. 
SEX: 
Male sex is associated with increased risk of stroke and poor outcome. 
RACE AND ETHNICITY 
Studies showed no statistically significant difference among the stroke 
patients belonging to different races. Some study shows that there is generally 
a higher incidence of all stroke types and cerebral infarction in blacks
8
. 
Previous stroke 
 Recurrence rate of cerebral infarction is 10-30%. The first 6 months is 
the period of highest risk if the patient did not take any treatment
9
. 
MODIFIABLE RISK FACTORS 
CIGARETTE SMOKING: 
 Cigarette smoking is a strongest risk factor for ischemic stroke and 
subarachnoid hemorrhage but there is less association with primary intra 
cerebral Hemorrhage. Smoking has been related to the extent of carotid 
disease in patients selected for angiography. Studies show that 50% increase 
risk in stroke occurrences in smokers. Heavy smoking causes doubling of  
risk
10
. In the Framingham study, cessation of smoking eliminates the 
additional risk of stroke within 2 years of stopping. 
ALCOHOL: 
Heavy alcohol consumption is also an independent risk factor for 
ischemic stroke. Studies show an association between sudden heavy drinking 
and the onset of cerebral infarction in young adults
11
. Chronic light alcohol 
intake carries decreased risk of stroke.  
 Chronic heavy intake of alcohol 180 – 400 g/week is associated with 
an increased risk. But modest alcohol consumption may be protective for 
ischemic stroke. 
BLOOD PRESSURE: 
  Hypertension aggravates the stroke risk by increasing the extent and 
severity of atheroma formation. Increasing blood pressure is strongly 
associated with increase in subsequent stroke risk with all the pathological 
types of small vessel disease with in the brain. Most studies considered the 
diastolic blood pressure most important risk factor. Prolonged treatment of 
diastolic BP to cause a decrease of 6 mm Hg decrease the stroke risk 
incidence by 40% and the benefits occur within 3 years
12
. The relationship 
with systolic blood pressure is found to be similar and possibly stronger, and 
even 'isolated’ systolic hypertension is associated with increased risk 13. 
Control of hypertension reduces the risk of stroke. 
BLOOD LIPIDS: 
          The association between blood lipids and stroke is weaker than that for 
coronary artery disease, but studies have shown that increase in serum 
lipoprotein(a) associated with increase in incidence of stroke
14
. Framingham 
study shows a weak correlation between cholesterol and triglycerides and the 
risk of cerebral infarction. 
DIABETES MELLITUS: 
 Diabetes mellitus can cause cerebrovascular atherosclerosis, cardiac 
embolism and rheological abnormalities and cause increase incidence of 
stroke. Diabetes mellitus increases the risk of cerebrovascular disease 2 to 4 
fold compared with non-diabetic patients
15
. Diabetes mellitus increases 
mortality rate in ischemic stroke patients.
 
ATRIAL FIBRILLATION: 
 The most frequent cause of embolic stroke is atrial fibrillation. Atrial 
fibrillation causes it by virtue of clot forming in the left atrium. Both 
rheumatic and non-heumatic atrial fibrillation is associated with ischemic 
stroke. Atrial fibrillation causes 20% of all infarcts
16
 and is associated with a 
relative risk of death from stroke. The risk of stroke is about 5% per year in 
non-rheumatic atrial fibrillation. 
Myocardial infarction 
 Cerebral infarction takes place in between 1% and 1.25% of cases 
within 1 year after myocardial infarction
17
. A history of myocardial infarction 
is also considered as a risk factor for cerebral infarction.
18
 
Other heart disease 
 Cardiac failure, coronary heart disease and angina increase the risk of 
cerebral infarction. While the hypertrophy of left ventricle quadruples the 
risk, independent of hypertension.
19
 
EXERCISE 
 Lack of physical activity is correlated with increased risk of ischemic 
stroke
20
. 
INFECTIONS AND INFLAMMATIONS: 
 There is evidence of an association between stroke and serum CRP
20
 
[C reactive protein]. High sensitive CRP [Hs CRP] elevated in case of 
inflammations and infections. High initial Hs CRP makes prognosis worse. 
The acute-phase reactant, CRP, a simple marker of inflammation, has now 
viewed as a major cardiovascular risk factor. CRP is composed of five 23-
kDa subunits. CRP mainly produced primarily from the liver. Studies have 
found that cells within human arteries, particularly in the atherosclerotic 
intima, can also synthesis CRP. Studies have demonstrated that CRP, when 
measured with high-sensitivity assays [Hs CRP] strongly and independently 
predicts risk of myocardial infarction, stroke, peripheral arterial disease, and 
sudden cardiac death. Most significantly, hsCRP predicts prognosis at all 
levels of LDL cholesterol and at all levels of risk and at all age group as 
determined by the Framingham risk score. 
 
Other markers of inflammation have predicted vascular risk. 
These include  
1, Interleukin-6, 
2, Intercellular adhesion molecule (sICAM-1), soluble forms of certain cell 
adhesion molecules, 
3, P-selectin, or the mediator CD40 ligand, as well as 
4, Myeloperoxidase- markers of leukocyte activation,  
5, Lipoprotein-associated phospholipase A2 and pregnancy-associated 
plasma proteinA - inflammatory markers associated with lipid oxidation. 
Some of these markers have very short half-life for use in clinical diagnostic 
testing, whereas the others predict risk in large populations very marginally 
with high cost. So, continued evaluation of other inflammatory biomarkers 
may be the next big targets for identification and monitoring of therapy, 
particularly in the case of acute ischemic stroke. 
Hyperhomocysteinemia.  
Studies showed that hyperhomocysteinemia related to ischemic stroke 
and coronary artery disease
21
. Homocysteine is an amino acid having 
sulfhydryl group. It is derived from the demethylation of dietary methionine. 
Patients with rare inherited deficiency of methionine metabolism will develop 
severe hyperhomocysteinemia. Plasma levels of homocysteine will be higher 
than 100μmol/liter [ normal up to 15 µmol/ liter].They have significantly 
elevated risk of premature atherothrombosis as well as venous thrombosis. 
Mechanisms responsible for these effects include endothelial dysfunction, 
accelerated LDL cholesterol oxidation, impairment of flow-mediated 
endothelium-derived relaxing factor with subsequent reduction in arterial 
vasodilatation, activation of platelets and their aggregation and oxidative 
stress. Mild to moderate hyperhomocysteinemia (plasma levels more than 
15μmol/liter) are more common primarily because of reduced dietary intake 
of folic acid. Heterozygotes for cystathionine synthetase deficiency have 
moderately raised levels of blood homocysteine. 
TRANSIENT ISCHEMIC ATTACKS: 
TIA [transient ischemic attack] has five to ten fold excess risk of 
ischemic stroke. About 15% of first ischemic stroke patients have had earlier 
TIAs, but only about 50% of them get consultation. So, the incidence of TIAs 
seeking medical care is an underestimate of the real problems.  
By definition, TIA has symptoms lasting for less than 24 hours, but 
few patients have some residual neurological signs of no functional 
significance and no symptoms. About 30% patients will have focal hypo 
density lesion on CT brain. Even higher percentage of patients has focal 
lesions on MRI.  
      The main aim of CT and MRI brain imaging is to find out any structural 
lesion causing 'transient focal neurological attacks'. 
 
 
Causes of transient focal neurological attacks 
1. TIA – cerebral ischemia 
2. Migraine with aura 
3. Partial epileptic seizures 
4. Space occupying intracranial lesions – tumour, hematoma etc 
5. vascular malformation, Giant aneurysm 
6. Multiple sclerosis 
7. Labyrinthine disorders 
8. Metabolic – hypoglycemia, hyperglycemia and electrolyte 
abnormalities 
9. Psychological 
CARDIOVASCULAR DISEASES: 
ECG abnormalities showing hypertension and coronary artery disease 
are risk factors for ischemic stroke. History of angina or myocardial 
infarction is highly associated with stroke incidence. Rheumatic heart disease 
and cardiac failure are other cardiac risk factors. Claudication is an additional 
risk factor for both stroke and myocardial infarction. Claudication reflects 
atheromatous disease in peripheral circulation. 
CAROTID ARTERY DISEASE: 
 When carotid artery stenosis is greater than three fourths of the 
circumference, combined transient ischemic attack
22
 and stroke incidence rate 
is 10.5% per year. 
PLASMA FIBRINOGEN: 
Fibrinogen itself is a strong independent risk factor for coronary artery 
disease and stroke. Plasma fibrinogen plays a role in platelet aggregation and 
contributes to blood viscosity, combines with thrombin and mediates the final 
step in clot formation. 
              Fibrinogen has been positively associated with age, obesity, 
smoking, diabetes, and LDL cholesterol level. It was associated inversely 
with HDL cholesterol level, alcohol and exercise level. Fibrinogen like CRP, 
is an acute-phase reactant and increases during inflammation. 
 Reports from various studies such as Gothenburg, Northwick Park, and 
Framingham heart studies all found significant positive associations between 
fibrinogen and future risk of cardiovascular events
23
.In one study, the age and 
gender adjusted hazard ratio per 1g/liter rise in plasma fibrinogen was 2.4 for 
coronary heart disease and 2.1 for stroke. 
 Qizibash N et al 
35
 identified in two prospective observational studies 
the importance of fibrinogen for prediction of ischemic stroke independent of 
other haemostatic factors such as Von Willebrand factor, tissue plasminogen 
activator and packed cell volume. 
 Fibrinogen should be included in the assessment of individual risk 
factors for ischemic stroke. Fibrinogen is the most significant potentially 
treatable risk factor for ischemic stroke. There are several mechanisms by 
which fibrinogen can promote thrombosis through hypercoaguable state, the 
acceleration of atherosclerosis or by reduction of blood flow by reducing 
vascular relaxation factor and or due to high blood or plasma viscosity. 
However high blood viscosity per se, has not consistently been found to be a 
risk factor for stroke. 
              In recent meta-analytic study, there was a significant linear 
logarithmic association between fibrinogen level and the risk of coronary 
heart disease and ischemic stroke. More studies showed that the prediction of 
risk of ischemic stroke will be high when both hsCRP and fibrinogen levels 
are utilized. 
OTHER RISK FACTORS: 
             Abdominal obesity, left ventricular hypertrophy, diagonal ear lobe 
crease, corneal arcus and snoring are other risk factors. 
CLASSIFICATION OF STROKE 
2, 24
 
Stroke can be classified in several ways 
PATHOPHYSIOLOGICAL CLASSIFICATION 
Ischemic 
TOAST trial of org acute stroke treatment – classified as 
A) Thrombotic 
-  Small vessel occlusion – [SVO] 
-  Large artery atherosclerosis - [LAA] 
B) Embolic 
- Cardio embolic occlusion - [CEO] 
- Artery – artery embolic 
- Unclassified 
- Hematologic 
- Others 
II Hemorrhagic 
i) Intra parenchymal 
ii) Subarachnoid 
B) Anatomic classification: 
I. by Vascular supply 
a. Carotid 
b. Vertebro basilar 
II. By location 
a. supra tentorial 
- Lobar 
- Ganglionic/thalamic 
b. Infratentorial 
          - Cerebellar 
PATHOLOGY 
            There are two major types of brain damage in stroke patients, 
1. ISCHEMIA: A lack of blood supply depriving brain tissue of needed fuel 
and oxygen. 
2. HEMORRHAGE: The release of blood into brain and extra vascular space 
within the cranium, which in turn damages the brain by causing localized or 
generalized injury. 
Cerebral ischemia can cause brain damage temporarily and 
permanently. Permanent damage cause cerebral infarction. 
It can be divided into a) thrombosis b) embolism and c) decreased 
systemic perfusion. 
Thrombosis: The most common pathology is atherosclerosis. They can block 
large arteries and penetrating arteries. Other common pathologies are arteritis 
(takayasu, giant cell etc.), fibro muscular dysplasia, dissection of vessel wall, 
and hemorrhage into plaque. 
Embolism:  Emboli formed elsewhere within the vascular system goes to 
distal vessel and blocks the blood flow. These arise proximally, more 
commonly from the heart, or from major arteries such as aorta, carotid, 
vertebral arteries and from systemic veins. 
Cardiac sources include from heart valves, endocardial surface and clot or 
tumors. 
Decreased systemic perfusion: Most commonly due to systemic 
hypotension, hypovolemia or cardiac pump failure. Poor perfusion will result 
in watershed zone infarct.  
Pathophysiology of acute cerebral ischemia 
Atherosclerosis 
              Atherosclerosis is a primary process responsible for vessel 
occlusion. It affects primarily elastic arteries [aorta, carotid, iliac arteries 
etc.]. Various studies described atherosclerosis not a simple disease of lipid 
deposition rather systemic inflammation plays a role in atherosclerotic 
plaque. Studies demonstrate heavy infiltration of inflammatory cells at the 
site of plaque rupture.  
            When cerebral blood flow falls and the brain become ischemic, a 
series of pathophysiological and functional changes occur before cell death.  
Cerebral ischemia causes not only reversible but also irreversible loss of 
brain function, when neurons are devoid of glucose and ATP. It also causes 
cerebral edema [Ischemic edema]. Cerebral edema is partly cytotoxic and 
partly vasogenic. Ischemic cerebral edema is maximum in 2-4 days and 
subsides within a week. 
  Cytotoxic edema starts within minutes of stroke onset. It affects the 
grey matter more than the white matter. It is because of damaged cell 
membrane that allows intracellular water to accumulate. 
  Vasogenic edema starts later, within hours of stroke onset. It affects 
the white matter more than the grey matter. It is due to the damaged blood-
brain barrier which allows plasma constituents to enter the extracellular 
space. 
DIAGNOSIS 
 The diagnosis of stroke is easy if there is any history of sudden onset 
of focal neurological dysfunction usually first noticed on getting up from the 
bed in the early morning. Patient will be over the age of 50 years and also has 
vascular risk factors. 
Progression of symptoms occur over the first few minutes or hours, but 
usually the deficit become stabilized by 12-24 hours and, the recovery starts 
within a few days in many cases. The severity ranges from a minimal deficit, 
which disappears in a day, through a persistent deficit with or without 
disability, to death. 
           If the history is clear, CT or MRI brain scan will show an infarct or 
hemorrhage. Brain imaging is normal in the case of early infarction or very 
small lesion. If there is any doubt about the speed of onset of a focal 
neurological deficit, the diagnosis is most likely to be an intracranial space 
occupying lesion, such as a tumor or chronic subdural hematoma. Intracranial 
tumor will have recent headache, seizures, papilledema and worsening of 
neurological deficit over long time.  
Chronic subdural hematoma patients will have 
1,  History of head injury in the previous few weeks;  
2,  Drowsiness, confusion and headache more than anticipated from the 
severity of the neurological deficit; 
3,  Fluctuating course of symptoms and  
4,      History of intake of anticoagulants. 
If the stroke onset was clearly sudden, but there was no obvious focal 
deficit, then brain imaging will show a thalamic or cerebellar infarct or 
hemorrhage. 
Other diagnosis to be considered 
Multiple sclerosis - young age 
Peripheral nerve or root lesion - clinical signs useful. 
Post-seizure hemiparesis – history helpful. 
Metabolic encephalopathy - global rather than focal neurological features.  
Somatization and hysteria - young age 
Encephalitis - fever, clinical symptoms and signs, diffusely abnormal EEG.  
Intracranial abscess - fever and predisposing cause such as otitis media, 
sinusitis and congenital heart disease etc. 
 
MIDDLE CEREBRAL ARTERY- SUPERFICIAL TERRITORY 
INFARCTS 
Superficial branches of the middle cerebral artery (MCA) form distal 
to the origin of lenticulostriate arteries. As they run in the subarachnoid 
space, they are called pial branches. They give the cortical, subcortical 
branches to frontal, parietal and temporal lobes after the MCA trunk and 
divide in to two (upper and lower) or three (upper, middle and lower) 
divisions. 
Because of characteristic feature of the pial artery network that is with 
multiple extensive anastomoses, multiple distal emboli are necessary to 
produce infarction. 
The etiology of embolism is large-artery disease (>50%) in internal 
carotid artery (ICA) or MCA occlusion in one third of the patients or cardiac 
disease in one quarter of the patients.  
INFARCTS IN THE TERRITORY OF THE DEEP PERFORATORS 
FROM THECAROTID SYSTEM 
 In comparison to the pial artery network, the deep perforators 
originated from the distal ICA or the MCA are terminal branches that 
perforate the basal part of the cerebral hemispheres. For that reason, 
occlusion of one or several perforators always causing an infarct usually is 
small. These small deep infarcts are called as Lacunar infarct which are 
caused by 
1. Microatheromatous or lipohyalinotic process associated with chronic 
arterial hypertension, 
2. Small hemorrhage or 
3. Dilatation of periarteriolar space. 
Embolism to the MCA trunk is a particularly common cause of 
complete lenticulostriate territory infarction [large striata capsular infarcts]. 
The artery of Heubner from the anterior cerebral artery (ACA) and the 
anterior choroidal artery from the carotid siphon are not only perforators, 
because they also supply cortical territories. 
ANTERIOR CEREBRAL ARTERY INFARCTS 
         ACA territory infarcts are less common than MCA infarcts by 20-30 
times. ACA, pial territory infarct cause mutism at the onset, crural 
hemiparesis, transcortical motor aphasia, frontal tasks impairment, grasp 
reflex, unilateral left apraxia, mood disturbance and incontinence. 
Simultaneous bilateral ACA infarction can occur due to the common origin 
of both ACAs. Symptoms will be akinetic mutism, incontinence and bilateral 
grasp reflex. 
BORDER ZONE CEREBRAL INFARCTS 
Infarction develops at the level of the extra territorial border zone 
between two main pial arterial branches. Those are commonly called 
watershed infarcts. They usually occur between the ACA and MCA 
territories anterior water shed infarcts or between the MCA and posterior 
cerebral artery (PCA) territories –posterior water shed infarcts. 
Anterior water shed infarcts  
Subcortical infarcts produce hemiparesis, predominating in the lower 
limb, with transcortical motor aphasia when lesion is on the left. Cortical 
infarcts produce proximal brachial hemiparesis. Bilateral anterior watershed 
cortical infarcts cause bi-brachial paralysis (man-in-the-barrel). 
Posterior watershed infarcts give picture that is similar to that of posterior 
MCA pial infarcts except for a more common occurrence of transcortial 
sensory aphasia. 
Bilateral watershed infarcts often have a symmetrical pattern. Sudden 
and profound hypotension cause bilateral infarcts in posterior boundary 
zones. 
A simple system separates stroke patients into four main clinical syndromes: 
total anterior circulation syndrome (TACS), partial anterior circulation 
syndrome (PACS), lacunar syndrome (LACS), and posterior circulation 
syndrome (POCS). This division depends entirely on the symptoms and 
signs. 
Next, CT or MRI brain imaging separates the patients with primary 
intra cerebral hemorrhage. Subsequently, based on community based studies 
infarctions shown by imaging are divided into four types 
Total anterior circulation infarct, about 15% of the total (TACI) 
28 29
; 
Partial anterior circulation infarct, 35% (PACI)
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;  
Lacunar infarct, 25% (LACI) 
32
; and 
Posterior circulation infarct, 25% (POCI). 
This classification gives some idea about prognosis, residual disability, and 
the chance of recurrence, and the cause of the stroke 
29
. 
TOTAL ANTERIOR CIRCULATION SYNDROME [TACS] 
          It is a characteristic clinical syndrome consisting of 
1. Contralateral hemiparesis with or without sensory deficit, involving the 
whole or at least two of three body areas (face, upper limb and lower 
limb) 
2. A homonymous visual field defect and 
3. A new higher cortical dysfunction (Dysphasia, neglect, visuospatial 
problems etc., depending on cerebral dominance).  
           Often patients are drowsy that any cognitive and visual field 
defects have to be assumed. 
          A large hematoma in one cerebral hemisphere or a massive infarct can 
affect the cortex
25
, basal ganglia and internal capsule and cause total anterior 
circulation syndrome. A large hematoma may cause midline shift, 
transtentorial herniation and coma within a day, whereas these changes need 
two to three days to evolve in massive infarct for cerebral edema to develop. 
PARTIAL ANTERIOR CIRCULATION SYNDROME [PACS] 
This clinical syndrome consists of  
1, only two of the three components of total anterior circulation 
syndrome [TACS], or 
2, Isolated cortical dysfunction such as dysphasia or 
3, Predominant proprioceptive deficit in one limb. 
             PACS is usually caused by occlusion of a branch of middle cerebral 
artery usually as a consequence of embolism from heart or proximal arteries. 
PACS is also caused by lobar hemorrhage. 
LACUNAR SYNDROME [LACS] 
              Lacunar syndromes are due to the lesions affecting the corona 
radiata, internal capsule, thalamus, cerebral peduncle, and pons. 
The four main lacunar syndromes are 
1. Pure motor deficit: 
               It is a unilateral motor deficit involving two of three areas (face, 
arm, leg). There are often sensory symptoms but no signs. The lesion is in 
internal capsule or pons. it makes about 50% of lacunar strokes. 
2. Pure sensory stroke:  
              Symptoms are sensory loss. It has the same distribution as pure 
motor stroke. The lesion is in thalamus. It is about 5% of lacunar strokes.  
3. Sensorimotor stroke: 
               Lesion is usually in thalamus or internal capsule. It averages about 
35%. 
4.Ataxic hemiparesis: 
              It is about 10% of all lacunar strokes. It is a combination of 
corticospinal and cerebellar lesions. Symptoms include dysfunction affecting 
arm and leg, dysarthria and clumsy hand. 
POSTERIOR CIRCULATION SYNDROME 
             Combination of brainstem, cerebellar, thalamic, or occipital lobe 
signs indicate significant infarction in the supply of the vertebrobasilar 
circulation, or a localized hemorrhage. Presence of both brainstem and 
occipital lobe signs is highly suggestive of infarction due to 
thromboembolism within the basilar and posterior cerebral artery (PCA) 
territories. 
            Proximal PCA occlusion causes enough temporal, thalamic and midbrain 
infarction to cause some contralateral hemiparesis and sensory loss with marked 
cognitive deficit such as aphasia, as well as homonymous hemianopia, causing  
confusion with occlusion of the middle cerebral artery or its branches. It is the so-
called 'walking total anterior circulation syndrome (TACS) because though it 
fulfills the definition of a TACS, the motor weakness is very mild.  
THALAMIC STROKE: 
           Infarction or hemorrhage of thalamus is uncommon. Thalamic stroke 
syndrome consists of paralysis of upward gaze, small pupils, depressed 
consciousness, disorientation, aphasia and impairment of verbal memory. 
CEREBELLAR STROKE: 
           Cerebellar stroke is also uncommon. Extensive infarction or hemorrhage 
causes vertigo, nausea, vomiting, horizontal nystagmus, incoordination, ipsilateral 
and truncal ataxia, as well as dysarthria. Some will have often brain stem signs. 
 
 
IMAGING OF THE BRAIN 
COMPUTERISED TOMOGRAPHY  
ISCHEMIC STROKE: The CT appearance of cerebral infarction is mostly time 
dependent. Though CT findings for ischemic stroke can be detected within 6-8 
hours of onset, CT can be normal up to 24 hours. 
CT findings in hyper acute infarct: 
- Can be normal in 50-60% cases 
- Hyper dense artery seen in 25-50% 
- Obscuration of lentiform nuclei can be seen. 
CT findings in acute Infarct 
- Loss of sulcal effacement 
- Loss of grey and white matter interfaces 
- (insular ribbon sign obscuration of cortico medullary border) 
- Low density basal ganglia 
CT findings after 1-3days of infarct 
Increasing mass effect 
- Wedge shaped low density area that involves both grey and white matter26 
- Hemorrhagic transformation may occur. 
 
CT findings after 4 days to 1 week 
- Gyral enhancement 
- Mass effect, 
- Edema persists 
After 1-8 weeks 
- Contrast enhancement persists 
- Mass effect resolves 
CT findings after months to years 
- Encephalomalacic changes 
- Volume loss 
- Rarely calcification 
 Early findings on CT may be effacement of adjacent subarachnoid 
spaces and loss of grey and white matter contrast enhancement. By 24 hours, 
the abnormal low attenuating area becomes clearly seen. Characteristically 
insular ribbon sign is defined as an early specific sign of MCA infarction. 
Early findings on non- contrast CT will be development of cytotoxic edema.  
 CT scan through the suprasellar will show hyper intense MCA. It is 
indicative of thrombus within the artery.  
 Combination of cytotoxic and vasogenic edema causes mass effect 
and decreased attenuation. Cytotoxic edema causing mass effect is 
maximum between 3-10 days, and may lead to herniation. Mass effect 
completely clears by 3 weeks. 
LACUNAR INFARCTION: 
 Because of the small size, CT may miss the lacunar infarct. Lacunar 
infarcts are secondary to arterial diseases which affect the deep penetrating 
vessels of brain. These arteries may show very small foci of sclerosis caused 
by micro atheroma or lipohyalinosis.  
MAGNETIC RESONANCE IMAGING OF STROKE 
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 Earliest MRI findings are vascular flow related abnormalities. These 
include absence of normal flow and slow flow with intravascular arterial 
enhancement. These signs can be seen within minutes of symptoms onset. 
Intravascular enhancement is seen nearly in 75% of acute cortical infarcts. 
Other early MRI findings will be hyper intense signal on T2 weighted 
images, which may not be seen within 8 hours. On both initial and follow up 
examinations the TI weighted images are sensitive. Acute infarcts are 
identified and diagnosed more on MRI as compared to CT. 
Course and Prognosis. 
    Several factors influence the immediate prognosis in cerebral 
thrombosis. In the case of very large infarcts, swelling of the infarcted tissue 
may occur, followed by displacement of central structures and tentorial 
herniation. Smaller infarcts of the inferior surface of the cerebellum can cause 
foramen magnum herniation and death. In basilar infarction associated with 
deep coma, the mortality rate is around 40 percent.  
Prognosis of ischemic stroke patients is better by 
1. Keeping the airway clear,  
2. Controlling brain edema, 
3. Preventing aspiration pneumonia, and 
4. Maintaining fluid and electrolyte balance. 
5. Control of respiratory and urinary infections. 
With smaller infarcts, the mortality is around 3 to 6 %. 
 Paralyzed muscles are flaccid in the first some days or week after 
stroke. Gradually spasticity appears, and the tendon reflexes appear more 
brisker. Posture of arm is in flexed adducted position, and the leg assumes an 
extended position. 
 On the other hand, early development of spasticity in the arm or the 
early appearance of a grasp reflex may predict a favourable prognosis.  
In some individuals with massive temporoparietal lesions, the hemiplegia 
remains flaccid. If the internal capsule is not damaged completely in a stroke 
but it involves the lenticular nucleus or thalamus then the patients will have 
hemichorea, athetosis, tremor, or ataxia, depending upon the particularly the 
lesion. Bowel and bladder control usually returns normally.  
         Often the hemiplegic limbs are at first tender and ache on manipulation. 
Physiotherapy should be initiated early to prevent contractures of muscles 
and periarthritis of the shoulder, elbow, wrist, knuckles, knee, and ankle. 
Sometimes atrophy of bone and pain in the hand may accompany the 
shoulder pain (shoulder-hand syndrome).  
         Feeling of dizziness and unsteadiness of gait often persists in case of 
damage to the vestibular system in brainstem infarcts. Recurrent seizures are 
relatively uncommon in thrombotic strokes. But they are about 20% in 
embolic cortical infarcts. When multiple infarcts occur over a long period, 
patients will have multi-infarct dementia. 
        Starkstein et al found out that fatigability and depression are more 
common in strokes that involve the left frontal lobe.   
FIBRINOGEN 
 In haemostatic system, fibrinogen is a main protein. At the end stage of 
clotting, thrombin changes soluble fibrinogen into fibrin monomers, which 
polymerize to a fibrin clot which is insoluble. At last, fibrinogen promotes 
platelet adhesion and aggregation via the αIIbβ3 integrin, thus inducing blood 
coagulation. Fibrinogen is also involved in platelet aggregation, regulation of 
Factor XIII activity and inflammatory reactions. Fibrinogen also plays a role 
in other physiological reactions including fibrinolysis, cellular and matrix 
interactions, wound healing and neoplasia.  
 Fibrinogen is a major determinant of blood and plasma viscosity. Raised 
fibrinogen levels predict future vascular events. 
 In plasma, concentration of fibrinogen is between 2 and 4 mg/mL (6 -
12 μM), and its half-life is about 3-4 days. Fibrinogen is a plasma 
glycoprotein that is mainly synthesized by liver hepatocytes. Fibrinogen is an 
acute phase reactant, it is up regulated two to eight times by interleukin 6 (IL-
6) and steroids during the acute-phase response to inflammation, infection 
and tissue injury. The fibrinogen levels varies with environmental and genetic 
factors, age, gender, BMI, race, season, smoking, physical exercise, diet and 
use of several drugs. 
Structure of fibrinogen 
 Fibrinogen molecules are elongated 45 nm structures. It consists of one 
central E region connected by α-helical coiled-coil segments to 2 peripheral 
D regions. The fibrinogen molecule comprises two sets of identical disulfide-
bridged halves. Each half consists of three polypeptide chains termed Aα, Bβ 
and γ. These six polypeptide chains assemble to make hexamer (AαBβγ) 2, 
joined together with 29 disulfide bonds. The fibrinogen molecule has at least 
12 domains, which are grouped into three major regions E, D and C regions. 
Both D and E regions has binding sites for fibrin assembly, cross-linking and 
platelet interactions. The two C regions are involved in fibrin assembly, 
activation of factor XIII, modulation of fibrinolysis and cell adhesion. 
    The common human fibrinogen molecule has 2964 amino acids and 
molecular weight of approximately 340 kilo Dalton (kDa). The Aα, Bβ and γ 
polypeptide chains have of 610, 461 and 411 amino acids with molecular 
weights of 68 kDa, 55 kDa and 49 kDa respectively. The 3 polypeptide 
chains Aα, Bβ and γ are encoded individually  by the fibrinogen alpha (FGA), 
fibrinogen beta (FGB) and fibrinogen gamma (FGG) genes, which are 
clustered in a region of approximately 50 kilobases (kb) and  they are located 
on chromosome 4q 23-32. 
 The central domain consists of a dimeric structure in which each dimer 
has the three amino terminals of the individual arms. The slightly thickened  

amino terminal ends of the Aα and Bβ chains indicate fibrinopeptides A and 
B, respectively. Fibrinopeptide A and B will not be seen in fibrin. The 
dimeric halves of the central domain are joined together by three of 11 
disulfide bonds. The rest of disulfide bonds are seen between the Aα and Bβ 
chains and in the junctions between the central domain and the coiled-
structures. These coiled-structures are made up of the single Aα, Bβ and γ 
chains super coiled as -helices. Six disulfide bonds in each coiled structure 
are reason for the super coil structure. They attached to the central and lateral 
domains in the form of disulfide rings. The basic structure consists of three 
pairs of polypeptide chains: α, β and γ, arranged like a mirror image. The 
amino acid residue arrangement is such that the inside of the coiled structure 
is hydrophobic and the outside of coiled structure is polar. 
 Each lateral domain have a mass of 67, 200 Da. Each domain is 
represented by random folds of the γ and β lobes. There are four carbohydrate 
clusters, each 2,500 Da. Two are placed on each lateral domain on the β chain 
and two located on each arm in the γ chain, near the central domain. TheAα 
polar appendage is the site of primary cross-linking. It is close to the carboxyl 
terminal of the γ chains. 
 Fibrinogen is degraded by plasmin yielding key fibrinogen fragments. 
It is a physiologic process that normally occurs in vivo. In the laboratory, 
plasmin digestion gives a group of fragments originally called as fragments 
A, B, C, D and E as determined by diethylaminoethyl chromatography. The 
fragments are labeled according to the order in which they form from the 
process. The intermediate products are called as Fragment X and Y. The X 
fragment is formed from breaking one of the coiled-coils midway between 
the central and lateral domain. It yields fragments D and Y. Further cleavage 
of fragment Y gives fragments D and E. 
 Plasma fibrinogen is synthesized exclusively by the hepatocyte, and 
the synthesis of the fibrinogen is under the coordinated control of three 
separate genes located on chromosome 4. Subsequently by assembly of the 
constituent polypeptide chain and the addition of carbohydrate side chains, 
the mature fibrinogen molecule is produced and secreted into the circulation. 
It has a half- life of 4 days and it has a fractional catabolic rate of 25% per 
day. 
Role of fibrinogen in three major functional processes. 
1. Conversion of soluble fibrinogen into insoluble fibrin during the process of 
blood coagulation.  
2. Activation of fibrinolytic system: The polymerized fibrin uses as a template for 
the localized assembly and activation of the fibrinolytic system, which modulates 
fibrin deposition and clot dissolution and 
 3. Fibrinogen binds and supports platelet aggregation and to endothelial cells, 
where it plays a role in tissue repair. 
Conversion of fibrinogen to insoluble fibrin –  
It can be divided into three distinct phases 
1. Thrombin cleaves fibrinopeptide by enzymes. 
2. Polymerization of fibrin, 
3. Factor XIII stabilizes fibrin by covalent cross-linking. 
Fibrin formation
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                 Thrombin breaks the Arg 16 Gly 17 bond of the Aα chain and the 
Arg 14 gly 15 bond of the Bβ chain. It results in the release of two molecule 
of fibrinopeptide A and two of fibrinopeptide B per molecule of fibrinogen. It 
forms fibrin monomer, which consists three chains called as the α, β and γ 
chains. 
           Though thrombin does proteolytic cleavage of FP-A and FP-B 
simultaneously, under physiological conditions, the cleavage of FP-B doesnot 
lead to fibrin formation. Nuclear magnetic resonance and x-ray 
crystallographic studies show that thrombin bind to a discrete segment of the 
N-terminal of the Aα chain of fibrinogen. Thrombin also binds to fibrin 
through a non-catalytic site called as fibrinogen recognition site, which binds 
to the N- terminus of the β chain. 
                 In intact fibrinogen, fibrinopeptides which are negatively charged 
play a role in maintaining the dispersion of individual fibrinogen molecules. 
Because next to their cleavage by thrombin, the resulting fibrin monomers 
polymerize spontaneously. 
Formation of protofibril 
                Polymerization of fibrin monomers involves the reciprocal non-
covalent interaction of molecular determinants in the frequent E region of an 
adjacent fibrin monomer. The resulting dimer is arranged in a half staggered 
overlap. Dimer continues to grow in length by the staggered addition of fibrin 
monomers. It results in the formation of two-stranded, half staggered polymer 
referred to as a protofibril, the basic structural unit of the fibrin clot. The 
final stage of fibrin formation is characterized by the factor XIIIa which 
forms covalent amide bonds between the E-amino group specific lysine 
residues and γ CONH2 groups of glutamine residues. These covalent bonds 
are first formed between the γ chains of two molecules. The dimerization of 
the γ chain occurred by bridges between Lys 406 of one γ chain and Glu 
398/399 of another. It is then followed by progressive covalent cross-linking 
of multiple-chains. Cross linking at branch points also produces D-trimers 
(or) D-tetramers. 
Platelet fibrinogen 
             In addition to plasma fibrinogen, the circulating blood also has very 
small pool of fibrinogen, which is present with in the platelet as granules. 
Few studies have shown that the fibrinogen is synthesized by the 
megakaryocyte, but more investigations showed that  both megakaryocytes 
and platelets are capable of internalizing fibrinogen from plasma by 
glycoprotein II b/IIIa mediated process. Platelet fibrinogen is deficient of γ 
chain. Platelet fibrinogen secreted after stimulation plays supporting role in 
hemostasis. 
Heterogeneity of fibrinogen 
             In healthy individuals, fibrinogen molecule has a high degree of 
heterogeneity that can occur in more than one million different forms as there 
are enormous possible combinations of genetic polymorphism, 
posttranslational modifications, alternative processing of messenger 
ribonucleic acids (mRNAs), and proteolytic degradation. Abnormal 
modifications are associated with diseases but more investigations are needed 
to prove them. 
Normal level of plasma fibrinogen is 190-350mg/dl.  But fibrinogen levels 
as low as 50% of normal or minimum 80mg/dl are sufficient for normal 
coagulation to proceed without any bleeding. Plasma fibrinogen levels more 
than 350mg/dl can be considered as hyperfibrinogenemia. Normal levels are 
varied between different laboratories and different assays. Various methods 
to measure fibrinogen levels are  
1. Clonable gravimetric method  
2. Functional method - Clauss 
3. Automated Nephalometric method 
4. ELISA - Enzyme Linked Immuno Sorbent Assay. 
                 ELISA is a highly specific test. It does not cross react with early 
products of fibrinogen degradations and can detect even one intact A chain of 
fibrinogen. It is suitable for estimation of fibrinogen after thrombolytic therapy. 
But functional methods are widely used especially Clauss method. 
               High fibrinogen is also influenced by genetic factors. Fibrinogen 
levels are under genetic control. About 20-50% inter individual variations in 
the fibrinogen levels were explained by genetic polymorphisms in fibrinogen 
gene. Most common polymorphism is - 455G > A in the promoter region of 
FBG-. It is strongest genetic variants associated with ischemic stroke in 
certain populations. Various studies revealed that FBG - gene was associated 
with raised fibrinogen levels. 
 
 
HYPERFIBRINOGENEMIA 
Plasma fibrinogen more than 350mg/dl can be considered as 
hyperfibrinogenemia. 
           Plasma fibrinogen levels rises significantly with age, with habits such 
as smoking, and in certain conditions such as hypertension, obesity and 
diabetes mellitus. Even, among normal individuals the plasma fibrinogen 
levels varies and although the exact reason is unknown. Recent studies tell 
that fibrinogen levels may be genetically controlled. High plasma fibrinogen 
levels have been observed in normal persons having a special nucleotide 
sequence polymorphism at the 5’ untranslated region of the Bβ chain. It 
seems to be a rate limiting step in fibrinogen biosynthesis. Increased 
transcription of this gene also results in elevated fibrinogen levels in a 
minority of the population.  
            In contrast, in most individuals fibrinogen plays as an acute phase 
reactant protein. Therefore it levels varied according to inflammation. In 
inflammations, the release of IL6 by macrophages results in increase in 
transcription of Bβ gene. It produces raised levels of fibrinogen. Elevated 
fibrinogen levels in ischemic stroke within 48 hours are not due to acute 
phase reaction. 
             Lip et al
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 reported that peak value of plasma fibrinogen occurred 
about 1 to 2weeks after onset of ischemic stroke. Tamamy et al 
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found that 
onset of peak of acute phase reactant fibrinogen and CRP was at about third 
day. Study of STAT & ESTAT showed that fibrinogen levels didn’t show 
significant rise till 5 days. Fibrinogen levels were monitored 3 hourly 
intervals in initial 12hr and every 12hr till day 5 of stroke. At baseline mean 
fibrinogen was 250mg/dl and at end of fifth day it was 210mg/dl and there 
was no significant elevation in the first five days.  
             Genetic polymorphism located within the IL-6 responsive element 
plays an important role in causing elevated fibrinogen levels in different 
individuals. This is distinct from the polymorphisms in the 5’untranslated 
region described above. The raised concentration of plasma fibrinogen has 
important clinical role, as indicated by several studies showing that 
hyperfibrinogenemia is an independent risk factor in stroke and in IHD. High 
Plasma fibrinogen concentration in the population increases the risk of CVD 
threefold as compared with those in the normal range of fibrinogen. Plasma 
fibrinogen level of one standard deviation (SD) (0.6 mg/ml) above the mean 
significantly multiplies the risk of CVD. When other risk factors for CVD 
and stroke such as age, sex, smoking, high BP, diabetes and serum 
cholesterol were considered, high levels of fibrinogen still emerged as an 
important risk factor. 
             Plasma fibrinogen has been demonstrated in atherogenesis and in 
arterial thrombus formation. Many studies have shown a significant impact of 
fibrinogen on cardiovascular disease incidence including stroke. Fibrinogen 
was also positively associated with many of the common risk factors for 
stroke including age, sex, smoking, hypertension, obesity and diabetes. 
Studies enlightening fibrinogen as a significant risk factor for ischemic stroke 
         Edzard Ernst and Karl Ludwig et al
23
 stated that fibrinogen can be 
viewed as a major cardiovascular risk factor and can be related patho 
physiologically related to vascular events after studied 92147 subjects. 
 A study conducted with 30 acute ischemic stroke patients & 30 acute 
ischemic stroke patients & 30 controls. Lipid profile, Plasma fibrinogen, 
platelet aggregation were estimated. They found that collagen induced 
platelet aggregation and plasma fibrinogen significantly higher in cases. No 
significant difference was seen in triglyceride, VLDL and HDL cholesterol & 
atherogenic index among cases & controls. There was also positive 
correlation between atherogenic index & fibrinogen. 
          AizhongGu and K.Sree Kumaran Nair et al stated that there was a 
strong association existed between atherosclerotic disease and fibrinogen 
levels and plasma concentrations of fibrinogen raised with age. This study 
also concluded that the raised levels of fibrinogen were due to a slower rate 
of disposal of fibrinogen rather than increased production rate. 
             Hazra B, Sengupta N, Saha SK et al
37
 in their study on plasma 
fibrinogen in stroke, explained that the increased plasma fibrinogen may be a 
significant risk factor for the thrombotic ischemic stroke. Koenig et al
36 
described the evidence on the pathogenetic role of fibrinogen in various 
vascular beds. 
             Thavaraj V; BehariM; Prasad K, et al
38
 did blood viscosity studies 
were in 14 patients with acute stroke, 8 with cerebral infarction, 6 with 
cerebral hemorrhage and thirteen controls and observed a statistically 
significant higher values of plasma and whole blood viscosity in patients with 
acute stroke than in normal controls suggesting that the hemorrheological 
factors play an important role in the pathophysiology of stroke patients. They 
found out that plasma fibrinogen levels were statistically higher (P<0.01) in 
patients than in normal controls. 
              Qizilbash et al
35
 identified importance of fibrinogen in two 
prospective observational studies. He found out that the association between 
fibrinogen & ischemic stroke were independent of other hemostatic and  
hemorrheological factors (VWF, Tissue Plasminogen activator and PCV) & 
plasma fibrinogen was the most important potentially treatable risk factor in 
ischemic stroke patients. Study supported accelerating influence of fibrinogen 
on atherosclerosis. Individuals with high fibrinogen but without any other 
risk factors should be considered for therapies to reduce fibrinogen levels. 
              Bo Kristensen, JanMalm&Colleagues
45
 Sweden found out increased 
fibrinogen levels & tissue plasminogen activator mass concentration were 
independently associated with ischemic stroke in young patients. 
              Lee , Lowe GD, M Woodword et al
33
 the related plasma fibrinogen 
to family history of premature heart disease, personal history of hypertension, 
diabetes, stroke and coronary heart disease. This large population based study 
showed that plasma fibrinogen levels are raised in patients with family 
history of premature heart disease and with personal history of hypertension, 
diabetes and obesity. 
Studies supporting fibrinogen as a good predictor of outcome of ischemic 
stroke 
              EUROSTROKE [UK, Finland and Rotterdam] large  cohort study 
showed that raised fibrinogen is a good predictor of stroke in 202 stroke 
patients and did not disclose  a differential relation with fatal or nonfatal 
stroke or with type of stroke whether hemorrhagic or non-hemorrhagic 
stroke. 
            Kim JH, Shin D.J, Park KH and his Colleagues
39
 in Korea conducted 
prospective study & evaluated that a raised level of plasma fibrinogen 
associated with large artery atherosclerosis (LAA) in acute ischemic stroke 
and with a poor clinical functional outcome. 
             WojcechTuraj and Agnieska Slowik et al
40
 compared plasma 
fibrinogen in patients with acute ischemic stroke and found that large vessel 
disease more significantly associated with high plasma fibrinogen than with 
small vessel disease. 
                Zhu – Yi Cheng, Li Ying, Beijing et al41evaluated 116 patients & 
found out that high fibrinogen in acute ischemic stroke predicted poor 
outcome. 
                 YezhuLycui Bi Hua conducted a case controlled  study  with 131 
ischemic stroke patients & 148 controls and found out that high fibrinogen 
was a risk factor and significantly correlated with subtypes of ischemic 
stroke. 
                 Peter M Roth well. Sally.C.Howard, Dermot A Power, Sergei 
A.Gutnikov and others
43
 studied 3 prospective studies of patients with TIA or 
minor ischemic stroke and found out that risks of acute ischemic stroke & 
TIA events increased linearly with elevated fibrinogen levels. 
                   A placebo controlled, randomized clinical trial study of patients 
from Bezafibrate infarction prevention study concluded that plasma 
fibrinogen was  a strong predictor of subsequent stroke rather than direct 
causative factor among the patients at increased risk. 
            MistryP.P, ChawlaK.P.RaiH.PJaiswal.P.P 
43
 studied 56 patients of 
stroke and found that high serum fibrinogen was present significantly among 
the stroke patients. 
           Wojciechturaj, AgnieshaSlowik, Tomasz Dziedzic Mateusz Adamski, 
Jack Strojny, Poland
44
 conducted a study to establish the significance of 
hyperfibrinogenemia as a possible predictor of 30 day and 1 year mortality in 
ischemic stroke patients and concluded that raised concentration of plasma 
fibrinogen shortly  after ischemic stroke independently ( >3.5g/L) increased 
risk of death within one year after ischemic stroke. 
            Another study with 185 patients having mild cognitive impairment 
showed that hyperfibrinogenemic had increased risk of dementia &vascular 
dementia. 
             A study was conducted in 56 patients of acute ischemic stroke & 42 
age & sex matched controls. Study showed mean plasma fibrinogen in 
patients 326.45 mg/dl -significantly higher than the control group. Smoking 
was described as a significant predictor of predictability of 36.7% for 
elevated serum fibrinogen. They adjusted other risk factors & at the end they 
found that plasma fibrinogen was found to be significantly high in patients 
compared to controls p < 0.001. They concluded that fibrinogen was a 
powerful predictor of ischemic stroke and did not predict the type and 
prognosis of stroke. 
           Northwick Park Heart study included white men 40 – 64years and 
tested for clotting factors including fibrinogen. Fatal coronary events and 
fibrinogen were significantly associated independent of other risk factors. 
Northwick Park Heart study included white men 40 – 64years and tested for 
clotting factors including fibrinogen. Fatal coronary events and fibrinogen 
were significantly associated independent of other risk factors. About 15 of 
24 died of IHD had fibrinogen level > 3.2g/L. 
            Speedwell study showed that fibrinogen levels measured by two 
different methods were associated significantly with IHD & its risk factors. 
             Caterphilly speed well collaborative heart disease studies revealed 
strong association of smoking with fibrinogen and the fibrinogen as a strong 
independent risk factor. 
             Gothenburg study - About 81% of target population [aged mean 54 
years] followed for 13.5 years. There were about 60 deaths, 37 strokes & 92 
myocardial infarctions Analysis ended that blood pressure and fibrinogen 
were risk factors for ischemic stroke and fibrinogen, smoking & cholesterol 
as risk factors for ischemic heart disease. This study was extended now to 
21year follow up and there were 333 deaths, 119 myocardial infarctions and 
81strokes. Conclusion of the study was fibrinogen was strongly statistically 
associated with stroke and mortality rate. 
Leigh study: Totally 505 men aged 40-69 years were followed up for 
7.3years. 40 cases of MI occurred. Fibrinogen was positively associated with 
MI incidence. When patients also had hypertension, incidence of MI was 
about six fold higher when associated fibrinogen levels more than 3.5g/L. 
Multivariate analysis showed predictive power of all risk factor variables in 
ascending order LDL, no of cigarettes smoked per day, obesity, cholesterol, 
blood pressure, age and at top of order plasma fibrinogen. Certain drawback 
of the study was highly selected population. It included only 76% of target 
population.  
Framingham study showed a stepwise increase in fibrinogen with smoking 
dose. 14 year follow up of patients showed increased incidence of risk for 
cardiovascular disease with raised fibrinogen levels in heavy smokers. 
PROCAM [prospective cardiovascular munster study] study
23
 investigated 
2817 patients of age 40-65years with no history of MI or stroke. About 55 
Cardiovascular events occurred in 1674 men in 4 years follow up period. 29 
of 55 events were having fibrinogen in upper terfile. 
GRIPS [Gottingen Risk Incidence and Prevalence] study - a prospective 
cohort study
23 
included 40 - 60 year aged men free of cardiovascular disease. 
About 107 myocardial infarctions occurred after 5 year follow up. Results 
showed fibrinogen a strong predictor in cardiovascular events. This study 
showed LDL had weak relationship with event occurrence but it was 
statistically significant. 
            Cumulative analysis from six prospective epidemiological studies 
(Gothenburg, Framingham, PROCAM, Northwick park heart study, GRIPS) 
showed that fibrinogen is an independent cardiovascular risk factor 
considering various study designs, sample composition, follow-ups & target 
points
23
. 
             A prospective study examined fibrinogen in 120 patients who had 
myocardial infarction. Reinfarction took place in patients with fibrinogen 
level more than 7.5g/L. 
              In a conducted study, out of 1716 men, who had MI followed for 2 
year, about 126 patients had developed further ischemic events. They were 
found to have elevated fibrinogen which is statistically significant. 
             Fibrinogen levels rise after an acute ischemic stroke. Earlier it was 
thought that elevated fibrinogen was due to an acute phase reaction due to 
brain necrosis. But now studies proved that fibrinogen levels significantly 
increased in patients with TIA where no infarction took place. It indicates 
that fibrinogen levels are elevated before stroke. 
Since there is significant increased risk of cardiovascular and 
cerebrovascular diseases associated with increased levels of plasma 
fibrinogen, the significant value of lowering fibrinogen in the primary as well 
as secondary prevention of atherosclerotic disease is now recognized as an 
important topic for global research. 
National Institutes of Health stroke scale 
55, 56 
The National Institutes of Health Stroke Scale [NIHSS] is a tool for 
assessing stroke severity and as an excellent predictor for patient outcomes. 
The NIHSS is composed of 11 items, each item ranges between 0 and 4. 
Score 0 means normal. Score 4 is indicating severe degree of neurological 
impairment. The maximum score is 42 and the minimum score is 0. 
Total score 21-42 indicates severe stroke. Score of 1-4 is minor stroke. 
Score of 5-15 is moderate stroke and 16-20 is moderate to severe stroke. It 
consists of 11 items containing level of consciousness, horizontal eye 
movement, visual field defect, facial palsy, motor arm, motor leg, limb 
ataxia, sensory, language, dysarthria and extinction and inattention 
Always patient’s first response to the task should be taken except 
language assessment where his best effort can be recorded
 
The NIHSS is a standardized and repeatable assessment tool in 
ischemic stroke patients utilized by large clinical studies. Consistency of 
NIHSS scores has been excellent in inter-personnel and in test-retests. NIHSS 
is then repeated at regular intervals. Follow up of scores can be used to 
monitor the treatment methods and evaluate patient’s improvement or 
decline. 
Rapid assessment of stroke severity by NHSS scoring reduces 
treatment delay of tissue plasminogen activator therapy. Current standard 
recommendation for treatment of acute ischemic stroke is tissue plasminogen 
activator therapy [tPA] and should be given within 4.5 hours of onset of 
stroke.  Some neurologists avoid tPA if NHSS score is less than 5. 
NHSS is summation of 4 factors i.e. left and right motor function and left and 
right cortical functions.  
Left cortical – loss of consciousness questions & commands and language 
Right cortical – horizontal eye movement, visual fields, sensory, extinction  
Right motor – right arm motor, right leg and dysarthria 
Left motor – left arm motor, left leg. 
   NIHSS gives more points on defects in the left hemisphere.  About 
98% of humans have verbal processing take place in the left hemisphere. 
   The NIHSS gives 7 of the total 42 points for verbal skills; It gives 2 
marks for the LOC questions, 2 marks for LOC commands, and 3 marks for 
the language. NIHSS is a better predictor of lesion volume in the strokes 
occurring within the left cerebral hemisphere.  
    NIHSS is found to be an excellent predictor of the patient outcomes. 
A baseline NIHSS score more than 16 indicates high probability of poor 
outcome, while NIHSS score less than 6 indicates a high chance of a good 
recovery. An increase of 1 point in a patient’s NIHSS score decreases the 
chance of a good outcome by 17%. 
The modified Rankin Scale [mRS] 
58,59
is a  very commonly used scale 
for measuring the degree of disability or dependence in the daily life of 
people who had ischemic stroke or other causes of neurological disorders, 
and it becomes the most widely used as functional outcome measure for 
stroke studies. We can reduce the Inter-observer reliability of the mRS by 
using a structured questionnaire during the interview. 
The scale has a value from 0-6, running from normal health without 
symptoms to death. Scale of more than 3 indicates poor outcome. 
MATERIALS AND METHODS 
Setting: 
This study was done in the Department of Medicine, Madurai Medical 
College and Government Rajaji Hospital, Madurai. 
Period of Study: 
From April 2012 to October 2012. 
Design of study: 
This is a prospective study of patients admitted with acute ischemic 
stroke new onset in Government Rajaji Hospital, Medicine Department 
Madurai. 
Sample Size: 
50 patients with acute ischemic stroke admitted in the Department of 
Medicine, Government Rajaji Hospital, Madurai  and 50 age and sex match 
controls were taken. 
Inclusion Criteria: 
All patients presented with acute stroke with definitive signs of 
neurological deficit and ischemic stroke was proved by CT brain. 
Hemorrhagic stroke was ruled out. 
Exclusion criteria: 
1. Patients with cerebral hemorrhage 
2. Individual with acute infection and inflammatory episode 
3. Patients with valvular heart disease 
4. Patients on anticoagulant therapy 
5. Patients with severe liver disease, renal failure 
6. Patients with absent peripheral pulses 
7. Pregnancy and Puerperium 
8. Women on oral contraceptive pills 
9. Patient’s undergone surgery within 3-6 months  
METHODS: 
Patients with acute ischemic stroke admitted in the medicine 
department were enquired about presenting complaints, mode of onset of 
neurological deficit, past history of TIA, hypertension, diabetes mellitus in 
detail. Special enquiry about alcoholism, smoking, pregnancy or recent 
delivery and use of anticoagulants or oral contraceptives was made. Any 
similar illness in the family was asked. BMI was identified. Complete general 
examination and neurological examination was done. Optic fundus was seen 
in all cases to identify papilledema, diabetic retinopathy and hypertensive 
retinopathy. Other systems were examined in detail. 
Basic investigations such as Hb, blood cell count, urine for albumin, 
sugar deposit, blood sugar, and urea serum creatinine and serum electrolytes 
total cholesterol were estimated. Electrocardiography, echocardiography and 
CT scan of brain were done. 
Serum samples for plasma fibrinogen estimation were taken after 
confirming ischemic stroke & sent to the laboratory. MRI brain was also 
taken if the CT brain was normal and if the patient was affordable. Other risk 
factors such as history of TIA, MI, SHT, DM and BMI & serum cholesterol 
were taken into account. NIHSS [National Institute Health Stroke Scale] 
Score at the time of admission were calculated. Patients are categorized into 
three groups [NIHSS<6, 6-14 and >14]. Standard treatment was given to all 
patients with ischemic stroke. They were adequately treated with anti edema 
measures, antiplatelets (aspirin alone), antibiotics, good nursing care and 
good physiotherapy. After 8 weeks of onset of stroke, all the patients were 
again followed up. Functional outcome were determined by use of Modified 
Rankin scale (MRS). All patients were stratified using MRS Scale [0-2,3-4 
and 5-6] into three groups . 
 Plasma fibrinogen level was correlated with NIHSS score at the time of 
admission and again with functional outcome using MRS score. Patients with 
MRS score of 5 and 6 were declared as very poor outcome & MRS of 3 and 4 
as poor outcome. Patients with MRS 0, and 1 were considered as good 
outcome. 
METHOD OF ASSAYING FIBRINOGEN IN PLASMA (CLAUSS 
METHOD)
48
 
Normal plasma fibrinogen level ranges from 190 to 350mg/dl. 
However the level more than 350mgs% can be considered as a risk factor as 
far as cerebrovascular disease is concerned. 
Fibrinogen was estimated by functional assay (clauss method) 
manually.  
First step is to dilute plasma (1:10) to minimize the effect of plasma 
inhibitory substances such as heparin, FDP etc. Diluted citrated plasma is 
made clotted using high concentration of thrombin (100 u/l) and now new 
coagulation time is directly proportional to the fibrinogen concentration. 
Testing process requires plasma (standard reference) with known level 
of fibrinogen measured against a well-known international standard. A graph 
is made using reference plasma by making serial dilutions (1:10 - 1:40) in 
buffers to give fibrinogen concentrations. Clotting time of each of these 
dilutions is found out and it is platted on [clotting time / fibrinogen] log - log 
graph paper. 1:10 concentration is 100% normal. 
 Test sample platelet poor diluted plasma (1:10 buffer) incubated 37
o 
C, 
phospholipid, thrombin & calcium are added. Time taken for clot to form was 
noted in calibration curve and from the curve fibrinogen level was deducted. 
STATISTICAL ANALYSIS: 
 The figures collected were recorded in a master chart. Statistical 
analysis was done using epidemiological package 2002 developed for WHO. 
KruskallWallis ‘Chi’ square test was used to see significance. A ‘P’ value 
less than 0.05 was taken to indicate significant difference among the 
variables. Pearson correlations were done between fibrinogen and NIHSS 
score and then with MRS value. Two tailed test was applied and significant P 
value <0.05 was considered as good correlation. 
OBSERVATIONS 
Table – 1 
Age Distribution 
Comparing incidence to age. 
Age in years No. of 
patients 
Percentage Male / Female 
< 40 4 8 3 / 1 
41 – 50 13 26 11 / 2 
51 – 60            17 34 13 / 4 
61 – 70 13 26 8 / 5 
> 70 3 6 3 / 0 
 
In age group 31- 40 there were 4 patients 3 male & one female. 
There were 13 patients in age group constituting 26 % in the age group 
41-50 years. 
In age group 51-60 there were 17 patients - (13 male & 4 female) 
making 34% of total cases 
In 61-70 year age group, 26% of total cases i.e. (13 patients) which 
have 8male & 5 female had ischemic stroke. 
Above 70yr age group only 3 male patients are there. 
  
 
 
 
 
 
 
 Table-2 
INCIDENCE WITH RELATION TO SEX 
Comparing incidence with sex 
Sex NO.OF 
PATIENTS 
PERCENTAGE 
Male 38 76% 
Female 12 24% 
 
Amounting 50 cases about 38 patients are males & 12 female 
constituting 76% & 24% respectively. 
  
 
 
 
 
 
 
 
 
 
 Table-3 
HISTORY 
Significant history 
HISTORY NO.OF PATIENTS 
Diabetes 23 
Hypertension 22 
Smoking 28 
Alcoholism 16 
TIA 8 
MI 14 
 
In our study, 23 persons are suffering from DM constituting46%. 
About 22 persons associated with SHT. about 28 individuals are smokers it is 
about 56%. 16 of the 50 patients are alcoholic [32%] 
 
 
 
 
 
 
 
 
  
 Table -4 
INCIDENCE OF SYNDROMES 
SYMPTOMS NO. CASES MALE FEMALE PERCENT 
TACS 7 5 2 14 
PACS 19 14 5 38 
LACS 15 12 3 24 
POCS 9 7 2 18 
 
Total anterior circulation syndrome constituted about 14%. Partial 
anterior circulation syndrome made up of 38%. Posterior circulation 
syndrome was about 18%. About24% of cases had lacunar syndrome. 
 Table-5 
AGE AND FIBRINOGEN 
Age Group Cases Control 
Mean SD Mean SD 
31-40 411.3 115.7 195 35.1 
41-50 389.6 135.6 216.1 58.6 
51-60 402.6 120.9 278.3 67.1 
61-70 391.2 120.6 265 80.1 
>70 448.3 63.3 341 40.3 
P Value 0.955  Not significant 0.011 Significant 
 
 Our study showed relationship between age & plasma fibrinogen in 
cases was statistically not significant [p = 0.955] and on the other hand it is 
significant in control [p = 0.011]. (<0.05) 
  
 
 
 
 
 
 
 
 
 
 Table-6 
SEX AND FIBRINOGEN 
Sex Cases Control 
Mean SD Mean SD 
Male 404.3 119.4 276.8 11.9 
Female 384.2 119.1 199.1 10.5 
P Value 0.612 0.002 
 
 In our study, no statistically significant difference between sex and 
plasma fibrinogen level in cases is established (P =0.612). But in control 
there is statistically significant difference exists (P=0.002). 
 
 
 
 
 
 
 
 
 
 Table-7 
DM AND FIBRINOGEN 
DM Cases Control 
Mean SD Mean SD 
Diabetes 383.9 96.3 313.4 65.7 
Non Diabetes 412.8 134.9 217.5 50.6 
P Value 0.396  Not significant <0.001 significant 
 In the study, relationship between diabetes & non-diabetics in cases 
was not statistically significant (P = 0.396). But in controls relationship is 
statistically significant (p = < 0.001). 
Table-8 
 FIBRINOGEN IN DM OF CASES VS CONTROLS 
DM  FIBRIOGEN 
Mean SD 
CASES 383.9 96.3 
CONTROLS 313.4 65.7 
P Value 0.007  Significant 
 
 This table shows that there is statistically significant difference in 
plasma fibrinogen among cases and controls. (p = 0.007) 
 
 
 
 
 Table-9 
HYPERTENSION  AND FIBRINOGEN 
HT Cases Control 
Mean SD Mean SD 
HT 428.4 105.6 286.5 78.2 
Non HT 376.8 124.8 245.9 70.1 
P Value 0.127  Not significant 0.068  Not significant 
 This table shows there is no statistically significant difference in 
plasma level of fibrinogen in hypertensive & non-hypertensive of both cases 
(p 0.127) controls (p -0.068). 
Table-10 
 FIBRINOGEN AND HYPERTENSION CASES vs. CONTROLS 
Hypertension  FIBRIOGEN 
Mean SD 
CASES 428.4 105.6 
CONTROLS 286.5 78.2 
P Value <0.001 
 
In our study, plasma fibrinogen statistically significantly associated 
with hypertensive patients in cases and controls (P = < 0.01). 
 
  
 Table-11 
SMOKING AND FIBRINOGEN 
Smoking Cases Control 
Mean SD Mean SD 
Smokers 419.6 126.6 245.6 72.9 
Non smokers 373.8 104.4 246.1 69.6 
P Value 0.178  Not significant 0.986  Not significant 
 
No statistically significant difference in smoking and nonsmoking among 
cases & controls (P= 0.178) and (P = 0.986) respectively. 
Table-12 
 FIBRINOGEN IN SMOKING CASES Vs CONTROLS 
GROUP  FIBRIOGEN 
Mean SD 
CASES 419.6 126.6 
CONTROLS 245.6 72.9 
P Value <0.001 
 
Fibrinogen level shows statistically significant difference among smokers of 
cases & controls (p <0.001). 
 
 Table-13 
ALCOHOLISM AND FIBRINOGEN 
 Cases Control 
Mean SD Mean SD 
Alcoholic 424.4 121.3 289.7 83.2 
Non 
alcoholic 
387.8 117.1 241.3 63.5 
P Value 0.313  Not significant 0.024 significant 
There is no significant difference between alcoholic and non alcoholic with 
fibrinogen among cases P=0.313 but there is significant difference among 
controls P=0.024 
Table 14 
ALCOHOLISM 
CASES VS CONTROLS 
 
Alcoholic 
Fibrinogen 
Mean SD 
CASES 424.4 121.3 
CONTROLS 289.7 83.2 
P Value < 0.001  Significant 
 
There is statistically significant difference P<0.001 existing between 
cases and controls for alcoholism. 
Table-15 
CHOLESTEROL AND FIBRINOGEN 
 
Cholesterol Cases Control 
Mean SD Mean SD 
<200mg/dl 385.2 127.0 245.7 66.4 
>200mg/dl 416.3 107.9 323.4 81.0 
P Value < 0.001  Significant 0.004 Significant 
 
 In our study, among cases & control there was statistically significant 
difference in plasma fibrinogen in patients with hypercholesterolemia > 
200mg & normal cholesterol levels. 
Cases - P < 0.001 
Controls P= 0.004 
   
 
 
 
 
 
 
 
 Table-16 
 FIBRINOGEN IN HYPERCHOLESTROLEMIA 
GROUP  FIBRIOGEN 
Mean SD 
CASES 416.3 107.9 
CONTROLS 323.4 81.0 
P Value 0.027 Significant 
 
Fibrinogen levels are statistically significant in hypercholesterolemia 
patients in cases & controls (P 0.027). 
 
 
 
 
 
 
 
 
 
 
 Table-17 
BMI AND FIBRINOGEN 
BMI Cases Control 
Mean SD Mean SD 
<25 353.65 97.2 233.65 58.1 
25-30 401.76 106.3 350.6 55.9 
>30 564.29 65.8 326.3 74.2 
P Value <0.001  Significant <0.001 Significant 
 
There was statistically significant difference in obesity (BMI>25) & 
plasma fibrinogen level  
Cases – (P<0.001) Controls- (P 0.001) 
 
 
 
 
 
 
 
 
 
 Table-18 
 FIBRINOGEN AND OBESITY 
CASES Vs CONTROL 
GROUP  FIBRINOGEN 
Mean SD 
CASES 449.2 121.2 
CONTROLS 342.5 60.3 
P Value 0.007  Significant 
 
There was a statistically significant difference between cases & 
controls with increased BMI. (P=0.007) 
 
 
 Table-19 
 FIBRINOGEN IN CASES Vs CONTROL 
 
GROUP  FIBRINOGEN 
Mean SD 
CASES 399.5 118.5 
CONTROLS 259.7 74.7 
P Value <0.001  Significant 
 
 Fibrinogen levels in cases and controls showed statistically 
significant difference among case and controls (P<0.001). 
                                                    Table-20 
NIHSS Score vs. FIBRINOGEN 
NIHSS  FIBRINOGEN 
Mean SD 
<6(10) 297.5 51.4 
6-14(17) 367.3 99.7 
>14(23) 467.6 112.1 
P Value <0.001  Significant 
 
About 23 patients had severe neurological deficit NIHSS>14 and they had 
mean fibrinogen=467.6mg/dl. About 10 patients had mild form of deficit 
NIHSS<6 and they had mean fibrinogen=297.5mg/dl. About 17 patients had 
mean fibrinogen of 367.3 mg/dl with NIHSS 6-14. 
  
 
 
 Table 21 
CORREELATION 
Serum fibrinogen  NIHSS 
 Pearson coefficient 
Two tailed T  -   P 
(significant) 
n 
 
0.7415 
0.000 
 
50 
 
Serum fibrinogen levels are significantly correlated with NIHSS Score by 
Pearson correlation(r=0.7415) and had significant P value =0.000. 
 
 
 
 
 
 
 
 
 
 Table-22 
MRS Vs. FIBRIONOGEN 
 
MRS  FIBRINOGEN 
Mean SD 
0 – 2   (28) 356.4 101.9 
3, 4   (20) 439.2 111.9 
5    (2) 605.0 21.2 
P Value 0.001  Significant 
About 28 patients are categorized in MRS scale 0-2 and mean fibrinogen is 
356.4mg/dl. Only 2 patients are in the severe degree of disability MRS scale 
5 with mean fibrinogen of 605mg/dl. About 20 patients are in MRS 3and 4. 
  
 
 
 
 
 Table 23 
CORRELATION 
Serum fibrinogen  Modified Rankin scale 
 Pearson’s coefficient 
Two tailed test  P 
Significant 
N 
0.5165 
0.0001 
 
50 
 
Serum fibrinogen values are statistically correlated with modified 
Rankin scale by Pearson correlation r=0.5165 and two tailed test P=0.0001 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 In our study population of 50 patients, the age of patients ranged from 
30 years to 75 years. There were 4 patients in age group of 31 to 40 includes 
3 male and 1 female. There were 13 patients in 41 to 50 age group includes 9 
males and 2 females. In the age group of 51–60 there were 17 patients of 
which 13 were male 4 were female. 13 patients in the age group of 61-70 of 
which 8 were males and 5 were females and 4 male patients. In the age group 
of more than 70 only 3 male patients are there. In those 50 patients 38 were 
male 12 were female patients indicating a male predominance. The incidence 
of major vascular risk factors was analyzed, Diabetes mellitus was found in 
46% of the patients. Hypertension was found in 44% of the patients. Smoking 
was present in 56% of the patients. Alcohol intake was present in 32% cases. 
History of coronary artery disease was present in 28% of the patients 
previous history of TIA was present in 16% of patients hypercholesterolemia 
found in 46% of the patients. BMI more than 25 found in 21 cases.  
 Total anterior circulation syndrome constituted about 14% [7 cases]. 
Partial anterior circulation syndrome made up of 38% [19 cases]. Posterior 
circulation syndrome was about 18% [9 cases]. About 24% of cases had 
lacunar syndrome [12 cases]. Plasma fibrinogen level was significantly 
increased with age advance in the control group [361mg/dl above 70 years] 
not in the cases. Male has high plasma fibrinogen value [276.8 vs. 199.1 
mg/dl] than female in the control group significantly. 
  Plasma fibrinogen level was elevated in hypertension [428.4 vs 
286.5mg/dl], diabetes [383.9 vs 313.4mg/dl], obesity [449.2 vs 342mg/dl] 
and hypercholesterolemia [416.3 vs 323mg/dl]. This finding is supported by 
Pai Mahesh et al
34
 and Lee et al study.  
About 23 patients had NIHSS score of more than 14 at the time of 
stroke which indicates the severity of stroke. They had mean fibrinogen 
467.6mg/dl. About 10 patients had mean fibrinogen 297.5 mg/dl and NIHSS 
<6 with mild neurological deficit. Only two patients had initial fibrinogen 
value of more than 600mg/dl and they had MRS scale of 5 after 8 weeks of 
stroke indicating very severe disability and outcome. About 20 patients had 
initial plasma fibrinogen at the time of stroke with mean value of 439.2 mg/dl 
and they had moderate disability after 8 weeks with MRS 3 and 4. 28 patients 
had MRS score of 0 and 1 after 8 weeks of stroke indicating no disability or 
very mild form of disability. These 28 patients had mean fibrinogen at the 
time of admission was 356.4mg/dl. 
AizhongGu and K. Sree Kumaran Nair et al stated that plasma 
concentrations of fibrinogen raised with age. This finding is present in our 
study significantly in controls.  
Grazilla Bruno, et al stated type 2 diabetic patients had a high 
prevalence of hyperfibrinogenemia and fibrinogen increased with age in men. 
This study supports our study. In our study diabetic patients had fibrinogen 
383.9mg/dl than controls 313.4mg/dl. Amanda J Lee, Gordon D Lowe, 
Mark
33
 in Scotland found that after adjustment for age, body mass index, and 
smoking, 74 male and 58 female diabetic individuals had higher serum 
fibrinogen concentrations than non-diabetic subjects. 
Pai Mahesh.C, Chandrasekhara P. et al
34
 studied the correlation 
between plasma fibrinogen levels and other major risk factors to ischemic 
stroke. This study compared 50 patients (proved to have cerebral infarction 
by CT scan) were compared with 50 controls. They were adjusted with 
respect to age and sex. Plasma fibrinogen was high among the males and 
increases with age. It was high significantly in diabetics when compared to 
non-diabetics. It was also statistically significant higher value in hypertensive 
and smokers. Hyperfibrinogenemia is associated with stroke recurrence and 
TIA. In our study plasma fibrinogen level was significantly increased in 
smoking, hypertension, diabetes, obesity and hypercholesterolemia.. 
Another study conducted with 30 acute ischemic stroke patients & 30 
acute ischemic stroke patients & 30 controls. Lipid profile, Plasma 
fibrinogen, platelet aggregation were estimated. They found that collagen 
induced platelet aggregation and plasma fibrinogen significantly higher in 
cases. No significant difference was seen in triglyceride, VLDL and HDL 
cholesterol &atherogenic index among cares & controls. There was also 
positive correlation between atherogenic index & fibrinogen. It supports our 
study in which patients with cholesterol more than 200mg/dl had fibrinogen 
(mean – 416.3 mg/dl) raised levels compared to the patients with normal 
cholesterol (mean fibrinogen – 385.2mg/dl). 
Gregoy del Zoppo &David.E.Levy&Colleagues
60  
analyzed placebo 
treated data from STAT (Stroke Treatment with Ancrod Trial) & ESTAT 
(European Stroke Treatment with Ancrod Trail)
47
. Fibrinogen level was 
estimated within 3 hours or 6hours of stroke. Functional outcome was 
estimated by Barthel Index Score at 90 days. Multiple logistic regression 
analysis was used. Fibrinogen levels increased from 340mg/dl (pretreatment) 
to 24 hour median value of 376mg/dl. Fibrinogen levels were classified as 
<350mg/dl, 350-450mg/dl, >450mg/dl. Good functional outcome was not 
produced in patients with high initial fibrinogen > 450mg/dl. In our study 22 
patients who had high initial fibrinogen mean value above 439mg/dl suffered 
severe disability with MRS score of 3 and above. Our findings coincided with 
Gregoy del Zoppo study
60
. 
STAT study showed that only 38 patients with high fibrinogen > 
450mg/dl having good functional outcome at 90 days were 19.2%. About 212 
Patients with lower initial fibrinogen <450mg/dl was 32.1% and they had 
good outcome. 
ESTAT study
47
: 92 placebo treated patients had fibrinogen >450mg/dl. 
Out of 92 patients, the proportion of patients with good functional outcome at 
90 days was 21.6%.About 523 patients with initial fibrinogen (<450mg/dl) 
had good functional outcome was higher 42%. It was statistically significant 
(P=0.0006). Proportion of patients achieved good outcome was more in 
lowest quartile of fibrinogen & more less in highest quartile. In our study 
about 28 patients with initial fibrinogen (356.4 mg/dl) had good functional 
outcome which was 56%. Our study was supported by this studty. Di Napoli 
et.al
49
 described that high fibrinogen level measured within 24 hours were 
significantly associated with death or new vascular disease. 52% patients who 
were in the upper tertile of fibrinogen levels had new vascular event. Around 
only 21.1% patients in the lower tertile had vascular event. But association 
was not significant with a multiple logistic regression analysis that included 
other risk factors age, initial stroke severity, diabetes and smoking. In our 
study there was no death and association between fibrinogen and stroke 
severity, diabetes and smoking was strong. 
Lip.et.al
50 
stated that no associations were found between mortality at 1 
year & fibrinogen levels in ischemic stroke patients.
 
Roth well et al
42
 identified associations was stronger for patient with 
nonlacunar than lacunar stroke for fibrinogen levels. Even adjusted for age, 
hypertension, smoking hyperlipidemia association was still significant (p 
0.04). In this study hyperfibrinogenemia was more in TACS and PACS 
compared to lacunar syndrome. 
U.Emre.U.Ergun, A.Unal et al
46
 studied 43 acute ischemic stroke 
patients & 37 control individuals. Serum fibrinogen, Ferritin, CRP level, 
WBC, ESR 24-72hrs were measured. Serum fibrinogen, CRP, ferritin were 
found out to be increased in cases than in control group. 
Delzoppo, David E Levy et al
60
 identified independent association of 
higher initial fibrinogen levels with poor outcome. Study suggested absolute 
need of treatment to reduce fibrinogen levels in treating acute ischemic 
stroke. In our study 22 patients who had high initial fibrinogen mean value 
above 439mg/dl suffered severe disability with MRS score of 3 and above.  
NINDS rt PA study
51 
[National Institute of Neurological Disorders and 
stroke] Fibrinogen levels didn’t rise at baseline after 2hr of initiation of stroke 
& 24hrs of onset of stroke. Higher first 24hr plasma fibrinogen levels resulted 
in 40% relative increase in mortality. In our study two patients had fibrinogen 
>600mg/dl in the first 24 hours of the stroke and there was no mortality. 
High fibrinogen [> 400mg/dl] will make clot thinner and more tightly packed 
with fibrinogen. Clot will then be very resistant to fibrinolysis. High 
fibrinogen is associated with high viscosity. Role of thrombolytic therapy 
plays a significant role when high fibrinogen levels are detected in early post 
stroke period. 
Gonzalez - Conejero et al
54
 evaluated fibrinogen levels in 200 stroke 
patients and concluded that acute ischemic stroke patients with fibrinogen 
level > 360mg/dl had poor outcome and also high 3 months mortality. They 
also suffered severe disability with NIHSS score > 15. Like that, in our study, 
about 23 patients with fibrinogen value of 467.6 mg/dl had NIHSS >14 and 
22 patients with fibrinogen more than 439.8 had poor outcome MRS > 3. 
KimJH, Shin DJ, Park KH, & their colleagues
39
 studied the functional 
outcome of ischemic stroke with plasma fibrinogen. Acute ischemic stroke 
was classified by TOAST classification, into three types [LAA -Large artery 
atherosclerosis, SVO -Small vessel occlusion, CEO - Cardio embolic 
occlusion].Serum fibrinogen was taken within 24hours of stroke. National 
institute of health stroke scale (NIHSS) assessed at admission and 4 weeks 
later & patients were divided into good group & bad group. Depending on 
plasma fibrinogen levels, patients were divided into normal group & high 
group (Plasma fibrinogen > 400 mg/dl). 
Out of 619 patients there were 251 patients with LAA. There were 229 
patients with SVO. They found that high plasma fibrinogen more than 400 
mg/dl (p < 0.001) was related to large artery atherosclerosis & high NIHSS 
score at admission and significantly related to poor prognosis. They 
concluded that an elevated level of fibrinogen (> 400mg/dl) significantly 
associated with larger artery atherosclerosis & poor functional outcome. In 
our study 22 patients who had high initial fibrinogen mean value above 
439mg/dl suffered severe disability with MRS score of 3 and above and had 
poor outcome. 
WojechTuraj, Agnieska slowik et al
40 
studied 203 patients. There were 
107 patients with small vessel disease and 96 with large vessel disease 
[LVD]. Fibrinogen level was higher in LVD patients 3.7 g/1 (2.9-4.9g/l) than 
in SVD -3.2 g/l (2.6-3.4g/l). They concluded that LVD patients with ischemic 
stroke have high fibrinogen (3.7g/l) & poor outcome. 
Zhu Yi cheng, Li-ying et al
41 
studied 116 patients with ischemic stroke 
for 2 years. Various factors such as age, gender, diabetes, hypertension, 
smoking, and alcoholism and lesion diameter were adjusted. They found that 
there were no significant difference in fibrinogen between LVD&SVD but 
high fibrinogen level was seen it large artery atherosclerotic type of ischemic 
stroke (3.30 ± 1.05g/L) (p <0.005) compared with small vessel disease (2.78 
g/l). They concluded that high plasma fibrinogen (3.3±1.05g/l) predicted the 
functional outcome within one year. 
Yczhu, Ly Chi in china et al correlated plasma fibrinogen level with 
subtypes of ischemic stroke. About 131 cases and 148 controls were selected. 
High plasma fibrinogen level (3.09 ± 0.94 g/L) p < 0.005 correlated with 
cerebral infarction at onset of disease. High fibrinogen (3.14 ± 0.81g/l) was 
significantly correlated with TACI, PACI [total and partial anterior 
circulation infarction] and posterior circulation infarction [p < 0.001] and 
with extra cranial arteriosclerosis and not with intracranial arteriosclerosis. 
This study correlated with our findings that high fibrinogen was associated 
with poor outcome and TACS,PACS and POCS. 
Peter.M.Rothwell, Sally.C.Howard, DermotA Power, 
SerginAGutnikov et al
42
studied 3 prospective studies of patients with TIA. 
Three trials UK TIA trial (n = 1860), Dutch TIA trial (n-2960) & oxford TIA 
study (n -293) founded out that high fibrinogen predicted subsequent 
ischemic stroke with hazard ratio for values above the median of 1.34 (95% 
CI, 1.13 to 1.60; P = 0.001) & predicted acute coronary events (HR = 1.42 
95% CI, 1.18 -1.70, P <0.001) & all ischemic stroke events (HR 1.24 95% 
CI, 90-1.70 P <0.001) and concluded that risks of recurrent ischemic stroke 
and acute coronary events increased linearly with fibrinogen level. 
About 140 stroke patient & 36 TIA patients from Bezafibrate 
infarction prevention clinical trial were studied. Plasma fibrinogen was 
measurement at admission and a year after. Occurrence of stroke was 
prospectively monitored as an end point. Results were mean fibrinogen were 
higher among the patients who have CVA (375 vs. 349 mg/dl. P < 0.001) & 
fibrinogen did not differ significantly by subtypes of CVA. They adjusted for 
age, blood pressure and other risk factors, high fibrinogen level (375mg/dl) 
were associated with more than twofold increased risk for ischemic stroke. 
MistryP.P, Chawla.K.P, RaiH.P.Jaiswall.P.P. et al
43
 estimated serum 
fibrinogen within 24hrs of ischemic stroke & identified elevated fibrinogen 
(513.73 ± 74 mg/dl) compared to age, sex matched control group & observed 
risk in fibrinogen level related to ischemic stroke rather than associated risk 
factors. Prospective study of 625 stroke patients, measured fibrinogen during 
rehabilitation period when acute phase response had subsided. Fibrinogen 
was statistically significantly high in them. Also they had second 
cardiovascular event within next 2 year. ODDS ratio were significantly raised 
for fibrinogen (3.67g/l; CI; 1.31 to 11.69) & plasma viscosity (2.86; CI 1.06 
to 8.4) independent of other risk factors. 
WojciechTuraj, AgnieszkaSlowik, Tomasz Dziezic, MaceuszAdamsk. 
Jacket Strojny
44
, Poland conducted a study in 900 ischemic stroke patients. 
They analyzed risk factors for stroke, neurological deficit and conscious level 
on admission and plasma fibrinogen was taken & registered vital statistics at 
1, 3, 6, 12 months after stroke. Mean plasma fibrinogen was 2.9g/l. About 
25.2 % patients had increased fibrinogen level i.e. >3.5g/L on the first day. 
Patients with hyper fibrinogenemia were more likely to expire after 1, 3, 6, 12 
months than those with normal levels. (21.1 Vs. 15.6%, 36 vs. 24%, 42 vs. 
27%, 45 vs. 31%. p < 0.001). Hyperfibrinogenemia predicted one year case 
fatality. Other factors predicted the prognosis were neurological deficit on 
admission, age, and WBC count and body temperature on day one. These 
studies predicted outcome like our study. 
Bokristensen, Jan malm, Torbjuvn
45
 Sweden studied 102 ischemic 
patients from 1991 - 1996 & 41 controls. Logistic multiple regression 
analysis showed that plasma fibrinogen was a strong predictor of ischemic 
stroke (odds ratio 11.25, 95% CI, 3.27 to 38.69).  
Studies showed that elevated level of fibrinogen is more significantly 
commonly associated with vascular dysfunction. At high level, fibrinogen 
increases cerebrovascular permeability by activating MMP [matrix 
metalloproteinase]. After fibrinogen infusion into male mice, pialvenular 
macromolecular leakage increased. This indicates that high fibrinogen 
damaged micro vascular integrity through activation of MMP -9 and down 
regulation of VE-Cadherin and up regulation of PV - 1 (plasmalemmal 
vesicle - associated protein). 
Fibrinogen levels rise after an acute ischemic stroke. Earlier it was 
thought that elevated fibrinogen was due to an acute phase reaction due to 
brain necrosis. But now studies proved that fibrinogen levels significantly 
increased in patients with TIA where no infarction took place. It indicates 
that fibrinogen levels are elevated before stroke. 
Lip et al 
50
 concluded that peak value of plasma fibrinogen occurred 
about 1 to 2weeks after onset of ischemic stroke. Tamamy et al
52
 stated that 
onset of peak of acute phase reactant fibrinogen and CRP was at about third 
day. Study of STAT &ESTAT
47
 indicated that fibrinogen levels didn’t show 
significant rise till 5 days. Fibrinogen levels were monitored 3 hourly 
intervals in initial 12hr and every 12hr till day 5 of stroke. At baseline mean 
fibrinogen was 250mg/dl and at end of fifth day it was 210mg/dl and there 
was no significant elevation in the first five days. So, in this study plasma 
fibrinogen was estimated within 48 hours of ischemic stroke after confirming 
with CT Brain. 
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
 There is a significant elevation of plasma fibrinogen in ischemic stroke 
patients compared to the age and sex matched control population. 
 Plasma fibrinogen can be used as a significant risk factor for acute 
ischemic stroke and other vascular events independent of other risk 
factors. 
 Serum fibrinogen levels can also be used as a prognostic indicator and 
high fibrinogen levels are well correlated with severity and outcome of 
acute ischemic stroke. 
 The primary goal of biomarker plasma fibrinogen in acute ischemic stroke 
patients should be early identification of high risk individuals who can be 
targeted for aggressive acute management and improved secondary 
prevention measures. 
 Many secondary prevention interventions like diet, exercise, smoking 
cessation and drugs [fibrates, omega 3 fatty acids, ticlopidine and 
pentoxifylline] all will reduce fibrinogen levels and minimize future 
vascular risk. 
 
 
 FUTURE STUDIES 
 Acute ischemic stroke prognosticator scores should be well defined 
and well accepted. 
 Secondary prevention strategies for ischemic stroke patients 
having fibrinogen level more than 350mg/dl should be analyzed 
and incorporated. 
 Clinical cut off points for fibrinogen levels should be standardized. 
 Long term safety of fibrinogen lowering agents will have to be 
established. 
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ABBREVIATION 
ATP  –  adenosine triphosphate 
CBF  –  cerebral blood flow 
CMRO2 -  cerebral metabolic rate of oxygen  
OEF  -  oxygen extraction fraction  
ACA  -  Anterior Cerebral Artery 
BMI  -  Body Mass index 
CT  -  Computerized Tomography 
CVA -  Cerebrovascular Accident 
CVD -  Cerebrovascular Disease 
DM  -  Diabetes Mellitus 
FPA  -  Fibrinopeptide - A 
FPB  -  Fibrinopeptide -B 
HT  -  Hypertension 
IHD  -  Ischemic heart disease 
MCA  -  Middle cerebral artery 
MRI  -  Magnetic Resonance Imaging 
TIA  -  transient ischemic attack. 
Hs CRP -  High sensitive C Reactive protein,  
sICAM-1 -  Intercellular adhesion molecule soluble forms  
LAA  -  Large artery atherosclerosis-  
CEO - Cardio embolic occlusion 
TACS  -  anterior circulation syndrome  
PACS  -  partial anterior circulation syndrome  
LACS  -  Lacunar syndrome  
POCS  -  posterior circulation syndrome  
TACI  - Total anterior circulation infarct 
PACI  -  Partial anterior circulation infarct  
LACI  -  Lacunar infarct 
POCI -  Posterior circulation infarct 
kDa  -  kilo Dalton 
FGA -  fibrinogen alpha  
FGB  -  fibrinogen beta  
FGG  -  fibrinogen gamma 
ELISA  - enzyme linked Immuno sorbent assay 
PROCAM -  prospective cardiovascular munster study 
GRIPS -  Gottingen Risk Incidence and Prevalence] study 
NIHSS  -  National Institutes of Health stroke scale  
MRS  -  modified Rankin Scale 
STAT  -  Stroke Treatment with Ancrod Trial 
ESTAT  -  European Stroke Treatment with Ancrod Trial 
NINDS  -  National Institute of Neurological Disorders and stroke 
LVD  - Large vessel disease  
SVD  –  small vessel disease 
 
 
 
 
 
 
 
                                               PROFORMA 
 
 NAME:                                        IP NO:                         SERIAL NO:  
 
AGE:             
 
SEX:  
 
OCCUPATION:  
 
ADDRESS:  
 
DATE AND TIME OF STROKE:  
 
 
DATE OF ADMISSION: 
 
STROKE RISK FACTORS  
                                                                                                   SHT   Y/N  
 
                                                                                                  DM     Y/N  
 
                                                                                       SMOKING     Y/N  
 
                                                                              ALCOHOLISM      Y/N  
 
                                                              HIGH CHOLESSTEROL      Y/N  
 
                                                                                                IHD     Y/N  
                                                                                                RHD     Y/N  
 
                                                                                                 AF      Y/N  
 
 
 
 
PAST HISTORY OF STROKE                                          :        Y/N  
 
CLINICAL EXAMINATION:  
 
PULSE RATE:                       BP:  
 
CVS:  
 
RS:  
 
ABDOMEN:  
 
CNS: 
 
 ACUTE STROKE SYMPTOMS AND SIGNS  
 
SYMPTOMS  
 
 
         HEADACHE   
 
        GIDDINESS   
 
        VOMITING   
 
        GAIT DISTURBANCE  
 
        CONVULSIONS  
 
         SPEECH DEFICIT   
 
-   
 
 
SIGNS  
 
       SPEECH DEFICIT  
 
       HEMIANOPIA  
 
       DIPLOPIA  
 
       MOTOR SYSTEM  
 
                      PARESIS AT ANY SITE  
 
                      PARESIS OF ARMS                     Y/N                    R/L/B  
 
                      PARESI OF LEGS                         Y/N                    R/L/B  
 
                      PARESIS OF FACE                      Y/N                     R/L/B  
 
                       FIRST INVOLVED                      FACE / ARMS /  LEGS 
 
                       NO SUCH ORDER                       Y/N  
 
                SENSORY DEFICIT                             Y/N  
 
                CEREBELLAR SIGNS                         Y/N   
 
 
 
 
MRS AFTER 8 WEEKS:                                    00/01/02/03/04/05/06 
 
INVESTIGATIONS:  
 
HB%:  
 
TOTAL COUNT:  
 
DIFFERENTIAL COUNT     P-       , L-        , E-       , M-       , B-  
 
ESR:  
 
BLOOD UREA:  
 
BLOOD SUGAR:  
 
SERUM CREATININE:  
 
SERUM ELECTROLYTES:  
 
LIPID PROFILE: 
 
PLASMA FIBRINOGEN:  
 
ECG:  
 
CT BRAIN AND FINDING:  
 
HAEMORRHAGE               :     Y/N  
 
INFARCT                           :     Y/N  
 
LOCATION                        :    ACA/MCA/PCA 
 
                                           WATER SHED/GLOBAL/LACUNAR/OTHERS  
 
 
 
 
 
 
 
 
 
 
 THE NATIONAL INSTITUTES OF HEALTH STROKE SCALE (NIHSS)                
                                                SCORE SHEET     
 
ITEM                                                                               RESPONSE                   SCORE 
1a. Level  of   consciousness                                   0 = Alert  
                                                                                 1 = Not alert  
                                                                                 2 = Obtunded  
                                                                                 3 = Unresponsive               
 
1b. Level of consciousness questions                     0 = Answers both correctly  
                                                                                1 = Answers one correctly  
                                                                                2 =Answers neither correctly         
1c. Level of  consciousness  commands (2)  
                                                                                0 = Performs both tasks correctly  
                                                                                1 = Performs one task correctly  
                                                                                2 = Performs neither task   
2. Gaze  
                                                                                 0 = Normal  
                                                                                 1 = Partial gaze palsy  
                                                                                 2 = Total gaze palsy  
3. Visual fields                                                             
                                                                                  0 = No visual loss                                               
                                                                                  1 = Partial hemianopia                                                  
                                                                                  2 = Complete hemianopia  
                                                                                  3 = Bilateral hemianopia   
 
-   
 
4. Facial palsy  
                                                                                  0 = Normal  
                                                                                  1 = Minor paralysis  
                                                                                  2 = Partial paralysis  
                                                                                  3 = Complete paralysis  
5. Motor arm  
 a. Left  
b. Right  
                                                                                   0 = No drift  
                                                                                   1 = Drift before 5 s  
                                                                                   2 = Falls before 10 s  
                                                                                   3 = No effort against gravity           
                                                                                   4 = No movement     R                   L 
6. Motor leg  
a. Left  
b. Right  
                                                                                  0 = No drift  
                                                                                  1 = Drift before 5 s  
                                                                                  2 = Falls before 5 s  
                                                                                  3 = No effort against gravity        
                                                                                  4 = No movement  
                                                                                                                        R             L       
 
 
 
 
 
 
 
 7. Ataxia   
                                                                                   0 = Absent  
                                                                                  1 = One limb  
                                                                                  2 = Two limbs  
8. Sensory  
                                                                                  0 = Normal  
                                                                                  1 = Mild loss  
                                                                                  2 = Severe loss  
9. Language  
                                                                                  0 = Normal  
                                                                                  1 = Mild aphasia  
                                                                                  2 = Severe aphasia  
                                                                                  3 = Mute or global aphasia  
10. Dysarthria  
                                                                                  0 = Normal  
                                                                                  1 = Mild  
                                                                                  2 = Severe  
11. Extinction / inattention  
                                                                                  0 = Normal  
                                                                                  1 = Mild  
                                                                                  2 = Severe  
DATE OF ADMISSION NIHSS SCORE                      
 
 
 
 
 
 
MODIFIED RANKIN SCALE (MRS) 
Score                   Description  
 0                   No symptoms at all  
 1                  No significant disability despite symptoms; able to carry out all 
usual     duties    and activities  
2                  Slight disability; unable to carry out all previous activities, but able 
to look    after own affairs without assistance  
 3                  Moderate disability; requiring some help, but able to walk without  
    assistance  
 4                 Moderately severe disability; unable to walk without assistance and 
    unable to attend to own bodily needs without assistance  
 5                 Severe disability; bedridden, incontinent and requiring constant 
nursing     care and attention  
 6                 Dead  
 
 
TOTAL (0–6):      ___ 
 
S.No. Name Age Sex Smoke alcoholic Diabetic HT Cholesterol BMI NHSS MRS fibrinogen symptom Sign CT MRI Syndrome history 
1 Murugesan 40 male Smoker alcoholic no DM no HT 127 28.1 12 1 465 GD,dysphasia, FD   R FP,SP,HP    R LT MCA I  PACS  
2 Palanisamy 71 male Smoker alcoholic no DM HT 140 23.3 28 4 425 ALOC,APHAS, GD,VD HP,FP,SP,ALOC MAS I L m+a  TACS TIA ,  CAD 
3 Papammal 62 female No no Diabetic HT 245 23.3 9 1 360 GD,dysphasia, FD FP,SP,HP    R MCAI  L  PACS  
4 Chandrasekar 55 male Smoker no no DM HT 221 28.8 24 4 500 GD HP    R N LAC INF L LACS TIA 
5 Subbiah 65 male No no no DM HT 130 24.1 4 0 380 GD, dysphasia,FD FP,SP,HP  L MCAI  R  PACS  
6 Nallathal 47 female No no Diabetic HT 230 24.5 10 1 410 GD, dysphasia,FD FP,SP,HP    R MCAI  L  PACS  
7 Ponnusamy 55 male Smoker no Diabetic no HT 220 29.2 5 1 315 GD HP    R N LAC INF L LACS  
8 Karuppaiah 45 male Smoker alcoholic no DM no HT 151 33.5 25 3 680 ALOC,APHAS, GD,VD ALOC,HP,SP,FP MAS I R m+a  TACS CAD 
9 Gajalaxmi 41 female No no Diabetic no HT 188 21.8 12 2 265 vom,gid, incoord nyst,CS PCA     L  PCS  
10 Anguselvan 52 male Smoker no Diabetic no HT 162 23.1 14 2 475 vom,gid,incoord nyst,CS PCAI     R  PCS  
11 Chellam 63 female No no Diabetic HT 212 28.9 12 2 280 GD, dysphasia,FD FP,SP,HP    R MCAI   L  PACS CAD 
12 Syed Kadher 52 male No no no DM HT 242 31.1 10 2 485 GD,FD HP,FP     R  LAC INF L LACS  
13 Muthammal 66 female No no Diabetic no HT 266 28.4 16 1 440 GD, dysphasia,FD FP,SP,HP    R MCAI   L  PACS  
14 Sundaram 46 male Smoker no no DM no HT 161 22.4 4 1 245 GD, HP,FP  L  LAC INF R LACS  
15 Annamalai 44 male Smoker alcoholic no DM HT 186 32.1 24 4 510 ALOC, APHAS,GD,VD ALOC,HP,SP,FP MAS I Rm+a  TACS TIA ,  CAD 
16 Raju 65 male Smoker no no DM HT 220 31.8 23 4 520 GD,dysphasia ,FD FP,SP,HP    R MCAI  L  PACS  
17 Pandi 67 male Smoker alcoholic Diabetic HT 156 27.1 8 2 290 GD,FD HP,FP      L N LAC INF R LACS  
18 Velmurugan 59 male Smoker alcoholic no DM HT 214 22.4 24 2 515 vom,gid,incoord nyst,CS PCAI     R  PCS TIA 
19 Thoppan 75 male Smoker alcoholic no DM no HT 168 29.2 21 3 520 GD, dysphasia,FD FP,SP,HP  L MCAI   R  PACS CAD 
20 Maruthamal 53 female No no Diabetic HT 160 24.1 16 1 420 GD HP     L  LAC INF R LACS  
21 Kasinathan 54 male No no no DM no HT 110 23.2 4 0 240 GD HP     R N LAC INF L LACS  
22 Solaiyan 38 male Smoker alcoholic Diabetic HT 158 28.8 23 4 540 GD, dysphasia, FD FP,SP,HP L MCAI   R  PACS CAD 
23 Mohdpitchai 62 male Smoker alcoholic Diabetic HT 220 29.7 12 3 420 GD,dysphasia,FD FP,SP,HP    L MCAI   R  PACS  
24 Veeranan 64 male Smoker no no DM no HT 116 21 5 1 250 GD HP     L  LAC INF R PCS  
25 Janaki 35 female No no no DM HT 175 25.4 8 3 275 GD,FD HP,FD     R  LAC INF L LACS  
26 Jeyakumar 45 male Smoker alcoholic no DM no HT 190 28.4 10 3 495 vom,gid,incoord nyst,CS PCAI     R  PCS CAD 
27 Samy 54 male Smoker no no DM no HT 175 21.5 4 1 240 GD,Dysphasia,FD FP,SP,HP    R MCAI   L  PACS  
28 Panchavarnam 56 female No no Diabetic no HT 185 24.1 12 3 345 GD,dysphasia,FD FP,SP,HP    R MCAI  L  PACS  
29 Palanisamy 63 male No no Diabetic HT 220 24.6 6 2 295 vom,gid,incoord nyst,CS PCAI   L  PCS CAD 
30 Chellaiya 30 male Smoker no Diabetic HT 215 29.1 16 3 365 GD,dysphasia,FD FP,SP,HP    R MCAI  L  PACS  
31 Kumaralaxmi 65 female No no Diabetic HT 246 28.5 28 5 620 ALOC,APHAS,GD,VD ALOC,HP,SP,FP MAS I Rm+a  TACS TIA 
32 Kandan 49 male Smoker alcoholic no DM no HT 195 24.6 16 3 375 GD,dysphasia,FD FP,SP,HP    L MCAI R  PACS TIA ,  CAD 
33 Samiappan 52 male Smoker alcoholic no DM no HT 235 27.5 4 0 350 GD HP   R N LAC INF  L LACS  
34 Kadhar Ali 52 male Smoker no no DM HT 260 24.1 28 4 570 vom,gid,incoord nyst,CS PCAI    R  PCS CAD 
35 Vellaiammal 60 female No no Diabetic no HT 185 23.1 5 1 320 vom,gid,incoord nyst,CS PCAI   L  PCS  
36 Ulaganathan 58 male Smoker no no DM no HT 130 32.1 28 1 590 ALOC,APHAS,GD,VD ALOC,HP,SP,FP MAS I L  TACS  
37 Mahalingam 48 male No no Diabetic no HT 110 24.1 10 1 355 GD HP   L N LAC INF  R LACS CAD 
38 Ravichandiran 45 male No no no DM no HT 146 22 12 2 535 GD,Dysphasia FD FP,SP,HP    R MCAI   L  PACS  
39 Raman 71 male Smoker alcoholic Diabetic no HT 138 24.01 16 3 400 GD,FD HP,FP    L  LAC INF  R LACS CAD 
40 Duraisamy Kasi 62 male Smoker alcoholic no DM no HT 215 26.7 18 2 325 GD,dysphasia,FD FP,SP,HP   R MCAI   L  PACS  
41 Kani 52 male Smoker no no DM HT 290 31 27 4 575 GD, Dysphasia, FD FP,SP,HP    L MCAI R  PACS  
42 Vijayakumar 60 male Smoker no no DM no HT 240 27.4 25 4 315 ALOC,APHAS,GD,VD ALOC,HP,SP,FP MAS I L  TACS  
43 Ayyanan 62 male No no Diabetic no HT 226 26 18 1 315 GD,dysphasia,FD FP,SP,HP    L MCAI R  PACS  
44 Alagar 58 male Smoker alcoholic no DM no HT 146 23.1 3 0 295 vom,gid, incoord nyst,CS PCAI    R  PCS CAD 
45 Pitchai 45 male No no Diabetic no HT 225 23 4 0 340 vom,gid, incoord nyst,CS P CAI   L  PCS  
46 Ilangovan 47 male No no Diabetic HT 200 24 15 3 360 GD,FD HP,FP   R  LAC INF L LACS  
47 Rakkayee 65 female No no Diabetic no HT 262 31.2 29 5 590 ALOC,APHAS, GD,VD ALOC,HP,SP,FP MAS I L  TACS TIA ,  CAD 
48 Thangapappan 45 male Smoker alcoholic no DM no HT 180 23.2 6 1 185 GD,FD HP,FP    L  LAC INF R LACS  
49 Samayee 55 female No no no DM no HT 175 21.6 16 4 285 GD HP       R  LAC INF  L LACS  
50 Nagar 50 male No no Diabetic HT 218 24.1 14 3 310 GD,dysphasia, FD FP,SP,HP   L MCAI R  PACS TIA 
                   
CONTROL 
S,No. Name Age Sex smoker Drinker DM HT Choles BMI fibrinogen 
1 ramasamy 57 male smoker alcoholic Diabetic no HT 192 22.6 370 
2 sivam  61 male smoker no no DM no HT 176 19.1 165 
3 samivelu 63 male no no Diabetic HT 190 24.1 280 
4 veerammal 67 female no no no DM no HT 172 18.9 160 
5 ponnusamy 78 male no no Diabetic no HT 152 23.2 295 
6 kuppusamy 64 male no no no DM HT 132 31.4 245 
7 samy 66 male no no Diabetic no HT 148 32.4 315 
8 nathan 63 male no alcoholic no DM no HT 98 19.1 235 
9 mohammed 48 male no no no DM no HT 115 21.2 160 
10 Raja 56 male no no Diabetic no HT 140 21.6 280 
11 arumugam 47 male no no no DM HT 200 22 216 
12 rakammal 59 female no no no DM HT 225 22.4 225 
13 murugan 57 male smoker alcoholic Diabetic HT 265 26.8 395 
14 kanagammal 58 female no no no DM no HT 170 19.1 155 
15 samiyandi 49 male smoker alcoholic Diabetic no HT 115 19.2 170 
16 pandeeswari 48 female no no no DM no HT 158 18.9 225 
17 revathy 36 female no no no DM no HT 118 22 170 
18 baskaran 58 male no no Diabetic no HT 135 22.6 265 
19 ramayee 51 female no no no DM HT 190 18.1 200 
20 laxmiammal 62 female no no no DM no HT 115 22.1 235 
21 muniasamy 50 male smoker alcoholic Diabetic no HT 236 20.4 360 
22 pandiyan 44 male no no no DM HT 140 24.1 160 
23 kaliammal 64 female smoker no no DM no HT 172 21.6 175 
24 rajamani 63 male smoker alcoholic no DM no HT 126 22.3 275 
25 abdul kadar 54 male smoker alcoholic no DM no HT 95 20.1 205 
26 saravanan 57 male smoker alcoholic no DM no HT 140 19.4 260 
CONTROL 
S,No. Name Age Sex smoker Drinker DM HT Choles BMI fibrinogen 
27 rajamanikam 52 male smoker alcoholic no DM HT 172 22.4 270 
28 rasiammal 64 female no no Diabetic HT 190 23.1 240 
29 kamarajan 72 male smoker alcoholic Diabetic no HT 160 27.2 375 
30 devaraj 74 male no no Diabetic no HT 170 32.4 320 
31 gurusamy 62 male smoker no no DM no HT 95 19.1 245 
32 sivaraman 63 male smoker alcoholic no DM no HT 166 21.2 260 
33 kumaran 73 male no no Diabetic no HT 170 29.4 375 
34 petchimuthu 62 male smoker alcoholic Diabetic HT 242 29 410 
35 kannabiran 56 male no no no DM no HT 116 21.2 330 
36 kalyanaraman 54 male no no Diabetic no HT 192 22.6 315 
37 sekaran 55 male no no Diabetic no HT 172 23.2 245 
38 muthukumaran 49 male no no no DM no HT 116 19.1 185 
39 kumaraguru 48 male smoker alcoholic no DM no HT 155 22.1 215 
40 sudar 66 female no no no DM no HT 140 24.7 165 
41 sadaiyan 38 male smoker alcoholic no DM no HT 90 24.6 220 
42 muniyandi 62 male no no Diabetic HT 192 26.5 350 
43 thambiran 52 male smoker alcoholic no DM HT 190 26.5 345 
44 kalairajan 39 male smoker alcoholic no DM no HT 130 24.3 160 
45 rajendiran 34 male smoker alcoholic no DM no HT 135 21.2 230 
46 seeni 48 male no no Diabetic HT 190 26.1 230 
47 raman 66 male smoker alcoholic Diabetic HT 266 31.2 425 
48 pachammal 44 female no no Diabetic HT 220 23.4 240 
49 palaniappan 65 male smoker alcoholic Diabetic HT 250 29.2 325 
50 chinnasamy 56 male no no Diabetic HT 220 23.4 315 
                      
MASTER CHART ABBREVIATIONS  
 
GD  - Gait Disturbance 
FD   - Facial deviation 
APHAS - Aphasia 
ALOL - Altered level of consciousness 
GID  - Giddiness 
Vom  – Vomiting 
Incord - Incoordination 
FP  - Facial Palsy 
SP  - Speech disorder 
HP  - Hemiplegia 
Nyst  - Nystagmus 
CS  - Cerebellar Signs 
R  - Right 
L  - Left 
N  - Normal 
LTMCA - Left middle cerebral artery 
I  - Infarction 
PCAI  - Posterior cerebral artery infarction 
m + a  - Middle cerebral artery & Anterior cerebral artery 
LACI  - LACUNAR Infarction 
PCS  - Posterior circulation syndrome 
TACS - Total anterior circulation syndrome 
PACS - Partial anterior circulation syndrome 
LACS - LACUNAR Syndrome 
 
  
 
 

  
